Compostions with enhanced bioavailability and fast acting inhibitor or gastric acid secretion

ABSTRACT

The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti- H. pylori  antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion. The present invention also relates to the use of one or more water soluble zinc salts, administered in combination with a therapeutic compound or agent (second therapeutic agent) which may be delivered orally with enhanced bioavailability (compared to compounds which are administered in the absence of water soluble zinc salts) or other favorable benefits. In addition, therapeutic agents which exhibit sensitivity to low pH may be advantageously orally administered in combination with an effective amount of at least one water soluble zinc salt. Compositions according to the present invention exhibit greater bioavailability of the active agent when formulated in combination with a water soluble zinc salt in oral dosage form than when administered with the water soluble zinc salt.

RELATED APPLICATIONS

This application claims the benefit of priority of U.S. patentapplication, Ser. No. 11/881,176, filed Jul. 26, 2007, entitled “FastActing Inhibitor of Gastric Acid Secretion”, said application beingincorporated by reference in its entirety herein.

FIELD OF THE INVENTION

The present invention relates to the use of pharmaceutically acceptablezinc salts, preferably water soluble zinc salts alone or optionally, incombination with one or more of a protein pump inhibitor (PPI), H2blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agentor a combination agent as otherwise described herein for providing fastaction with optional long duration effect in reducing gastric acidsecretion, including acid secretion in the fundus (by inhibitingvacuolar H⁺-ATPase or H⁺/K⁺-ATPase) and upper body region of the stomach(by inhibiting H⁺/K⁺-ATPase), thus raising the pH of the stomach duringresting phase as well as decreasing the duration of stomach acid releaseduring a secretagogue phase and for treating conditions includinggastroesophogeal reflux disease (GERD), non-erosive reflux disease(NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, andgastric cancer, as well as preventing or reducing the likelihood ofulcer disease. In addition, the present methods are useful for treatingpatients who are non-responsive to proton pump inhibitors (PPI) and asan alternative to traditional therapies or conditions which are causedby rapid and complete inhibition of secretagogue induced acid secretion.

The present invention also relates to the use of one or more watersoluble zinc salts, administered in combination with a therapeuticcompound or agent (second therapeutic agent) which may be deliveredorally with enhanced bioavailability (compared to compounds which areadministered in the absence of water soluble zinc salts) or otherfavorable benefits. In addition, therapeutic agents which exhibitsensitivity to low pH may be advantageously orally administered incombination with an effective amount of at least one water soluble zincsalt. Compositions according to the present invention exhibit greaterbioavailability of the active agent when formulated in combination witha water soluble zinc salt in oral dosage form than when administeredwith the water soluble zinc salt.

BACKGROUND OF THE INVENTION

The generation of concentrated 0.16N hydrochloric acid by the mammalianparietal cell involves a complex combination of neuronal and hormonalregulatory feedback loops¹⁻³. Following activation of the cell there isa complex cellular transfer of ions that allows for the formation ofacid⁴⁻⁷. A disruption in any of these components (secretory receptors,or ion transporters) can lead to either a cessation in the secretion ofacid, or in the hypersecretion of acid. In the latter over 30 millionpatients per year suffer from symptoms of acid related diseases with thenumbers increasing yearly⁸⁻¹¹. Clinically the uncontrolled release orthe continued hypersecretion of acid can lead to changes in both gastricand intestinal epithelium, but can in more serious cases lead toerosions of the esophagus that can result in metaplasia and death¹²⁻¹⁴.Recent evidence has also emerged that prolonged recurrent periods ofhypersecretory states can lead to gastric carcinoid formation¹⁵.

In an attempt to design therapies to prevent hyperacid secretion avariety of approaches have been employed in recent years with two of themost successful being: a) inhibition of the Histamine receptor on thebasolateral membrane of the parietal cell, b) proton pump specific drugstargeted against the H⁺,K⁺-ATPase (the so called proton pump inhibitors;PPI)¹⁶-18. Both of these therapies have greatly improved the quality oflife for patients suffering from this disease, however there is an everincreasing number of patients that have experienced recurrent diseasewhile still taking the drugs^(19, 20). Despite their high degree ofefficacy and worldwide clinical use, failure in the treatment of acidrelated diseases has been reported and the degree and speed of onset ofsymptom relief are important to patients²¹. It has been estimated thatabout 30% of GERD patients remain symptomatic on standard dose of PPI²².Furthermore PPI's have a short plasma half life which often leads tonocturnal acid breakthrough²³. Therapeutic oral doses of PPIs reachsteady state and thus achieve their maximal effective levels after 4-5days with typical dosing regimens²⁴. This slow and cumulative onset ofeffect of PPIs relates to their ability to inhibit only those pumpswhich are active when the PPI drug is available. After PPIadministration, there is a return of acid secretion that is partly dueto de novo synthesis of the enzyme²⁵.

Zinc is an essential part of the diet that all cells require in order tomaintain membrane integrity and function. Deficiency in intracellularzinc leads to apoptotic events, and cell death²⁶⁻³⁰. Previous studieshave investigated the potential role of zinc in the proliferation andgeneration of the protective barrier, namely the mucous gel layer at thesurface of the stomach³¹⁻³⁴. These studies falsely attributed thereduction in acid secretion to an increase in the thickness of the gellayer.³³⁻³⁵.

Gastric acid aids protein digestion; facilitates the absorption of iron,calcium, and vitamin B12; and prevents bacterial overgrowth. When levelsof acid and proteolytic enzymes overwhelm the mucosal defensemechanisms, ulcers occur. To avoid damage that is associated with theseharsh conditions, gastric acid must be finely regulated by overlappingneural (e.g. acetylcholine), hormonal (e.g. gastrin and ghrelin), andparacrine (e.g. histamine and somatostatin) pathways, and more recentlyvia the Calcium Sensing Receptor. Any long term alterations in any ofthese regulatory pathways leads to cell and tissue destruction andclinical manifestations such as peptic ulcer diseases, orgastroesophageal reflux disease (GERD). Two methods are commonlyemployed to treat the overproduction of acid: a) surgically, byelimination of the neuronal element (vagotomy) or b) pharmacologically,either through histamine 2 receptor antagonists or proton pumpinhibitors (PPI's) or a combination of both.

PPI's such as omeprazole are irreversible inhibitors of the gastricH⁺,K⁺-ATPase, recently various derivatives of the parent compoundomeprazole that bind to multiple cysteine residues on the exofacialsurface of the H⁺,K⁺-ATPase have been developed in hopes of having atighter molecular binding, and longer action have been employed. Bothrabeprazole, and lansoprazole are examples of these multiple bindingdrugs and are activated in the acidic lumen of the gastric gland andmodify the cysteine residues located on the luminal surface of theH⁺,K⁺-ATPase. In the resting cell the acid secreting pumps areinternalized in a system of tubular vesicles, and are in such aconformational state that the PPIs can only inhibit the H⁺,K⁺-ATPaseswhich have already been activated and transferred to the apical surfaceof the parietal cell.

Although optimizing pharmacological profiles within the PPI class mayprovide some clinical benefit, other areas of research may prove to bemore fruitful and furthermore the fine tuning of the acid secretoryprocess is still not completely understood and remains an importanttarget for therapies to modulate gastric acid secretion.

Zinc is required for a large number of biological processes includinggene expression, replication, membrane stability, hormonal storage andrelease and as a catalytic component for enzymes. There has been noinvestigation of the actions of zinc at the cellular level relating toeffects on acid secretion.

Helicobacter pylorus resides within the mucous layer of the humangastric mucosa. Due to extremely low pH, the stomach is a hostileenvironment to most other microorganisms. The ability of H. pylori toflourish in the stomach has been attributed to protective mechanismssuch as its production of urease, protecting the bacterium from gastricacidity by creating a basic microenvironment, See, Taylor and Blaser,Epidemiol Rev, 13:42-59, (1991).

The stomach is a large organ that can be divided into 3 main zones thatare involved in the process of digestion of foodstuff and thesterilization of liquids and water. When defining the functional processof the stomach it has been commonly divided into two zones: UpperStomach, and Lower Stomach. The upper stomach, is thought to be composedof the fundus and upper body, and shows low frequency, sustainedcontractions that are responsible for generating a basal pressure withinthe stomach. Of note is that these tonic contractions also generate apressure gradient from the stomach to small intestine and areresponsible for gastric emptying. Interestingly, when swallowing foodand the consequent gastric distention that occurs acts to inhibitscontraction of this region of the stomach, allowing it to balloon outforming a large reservoir without a significant increase in pressure.The lower stomach is thought to be involved in the grinding andliquefaction of the foodstuffs by the secretion of HCl from the parietalcells found in this section of the stomach.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A-E shows the original tracing of basal acid secretion, histamineinduced acid secretion and inhibition by ZnCl₂. Single human and ratgastric glands were isolated, loaded with the pH-sensitive dye BCECF tomeasure intracellular pH over single parietal cells and the pH, recoveryrate was calculated from the slope after an acid load using the NH₄C1prepulse technique. (A,C) Intracellular alkalinization stimulated byhistamine (100 μM) in the absence of extracellular Na⁺ as a function ofH⁺/K⁺-ATPase in gastric glands. (B,D) Histamine induced proton effluxfrom gastric glands can be blocked by 300 umol ZnCl₂. (E) Bar graphsummarizing data as means SE (control: n=32 cells, 3 gland, 3 animals;histamine: n=120 cells, 15 glands, 8 animals; histamine+ZnCl₂: n=60cells, 6 gland, 4 animals).

FIG. 2 shows that ZnCl₂ inhibits acid secretion in a dose dependentmanner. ZnCl₂ concentration dependence of H⁺/K⁺-ATPase activity(intracellular alkalinization expressed as ΔpH/min) in the presence of100 μmol histamine in comparison to basal and histamine induced acidsecretion. (n=40 cells, 3-4 glands, 3-4 animals for each ZnCl₂concentration).

FIG. 3 show the fast onset inhibitory effect and reversibility withZnCl₂. (A) original tracing shows the fast inhibitory effect of ZnCl₂ onhistamine induced acid secretion. Histamine (100 μM) was added throughthe whole experiment. When the intracellular alkalinization(protonefflux) was observed, ZnCl₂ (300 μM) was added to the superfusionbath. The acid secretion was abolished after a few seconds (flat middlepart). After the removal of ZnCl₂ out of the perfusion bath the drug waswashed out and the increase of the intracellular pH continued. (B)Original tracing shows the reversibility after the cells where incubatedand superfused over 20 min with ZnCl₂ (300 μM) and histamine (100 μM).After removal of ZnCl₂ out of the superfusion bath the intracellularalkalinization (proton extrusion) occur.

FIG. 4 shows acid secretion after oral ZnCl₂ application. 300 μmol ZnCl₂was added to the drinking water. Animals ate and drank as much ascontrol animals. Prior the experiment they were fasted for 12-18 hours.The histamine induced acid secretion was measured as described before.The cells of the ZnCl₂ treated animals showed a lower rate of protonefflux. 150 mg/kg/d: 0.022±0.0045; (n=60 cells, 10 glands, 3 animals),0.05 mg/kg/d: 0.034±0.0036; (n=60 cells, 6 glands, 4 animals).

FIG. 5 shows that ZnCl₂ inhibits gastric acid secretion in freshlyisolated rat whole stomach preparation. Ex vivo rat whole stomachpreparations were incubated in HEPES-buffered Ringer solution (control:n=9), HEPES-buffered Ringer solution plus 100 μM histamine (n=8), orHEPES-buffered Ringer solution plus 100 μmol histamine and 300 μmolZnCl₂ (n=8). Stomach preparations incubated with histamine and ZnCl2 hada higher pH than those in HEPES-buffered Ringer solution and histamineand their pH was similar to the pH of the control stomach.

FIG. 6 shows measurements of whole stomach intraluminal pH using anumber of zinc salts according to the present invention. Isolated wholestomach preparations from rats were cannulated at the esophageal andduodenal junction and perfused in vitro with 37° C. pH 7.4 Ringerssolution. The blood perfusate was then exposed to 100 μM Histamine toinduce acid secretion. The lumen of the stomach was infused with 0.5 ccof non-buffered isotonic saline. In some studies one of the followingzinc salts was added to the lumen perfusate at a final concentration of300 μM (zinc chloride, zinc sulfate, zinc acetate, zinc citrate). Thedata are the sum of 5 separate stomachs from 5 separate animals for eachof the columns. Data are the mean of all studies with the standard errorof the mean displayed.

FIGS. 7A-C show the immunohistochemistry in rat stomach fundus. (A)Immunolocalization of the gastric H⁺, K⁺-ATPase a subunit in rat fundicgland parietal cells (40×). (B) Fundic parietal cell Electron Microscopyof Gold Tagged H⁺, K⁺-ATPase protein. Here the nucleus, apical membraneand canaliculus like structure can be seen (8,000×). (C) Highermagnification (25,000×) of the same cell. Here the gold tagged H⁺,K⁺-ATPase protein can be seen distributed at the borders of thecanaliculus like structure (arrows). (In this figure: n=nucleus,c=canaliculus like structure, am=apical membrane)

FIGS. 8A-D show the original tracing of basal acid secretion andhistamine induced acid secretion in the gastric fundus and corpus.Single rat gastric glands were isolated, loaded with pH sensitive dyeBCECF to measure intracellular pH of Single parietal cells and the pHirecovery rate was calculated from the slope after an acid load using theNH₄CL prepulse technique. (A) Original tracing of an F1 glandalkalinization (proton efflux) after removing Na⁺ out of the perfusionbath. (B) Intracellular alkalinization of an F1 gland stimulated byhistamine (100 μM) in the absence of extracellular Na⁺ as a function ofH⁺, K⁺-ATPase. (C) Tracing of a corpus gland alkalinization underresting condition. (D) Intracellular alkalinization of an corpus glandstimulated by histamine (100 μM) in the absence of extracellular Na⁺ asa function of H⁺, K⁺-ATPase.

FIG. 9 shows a secretagogue series of F1 glands. F1 gland under basalcondition with no stimulation shows alkalinization rates of 0.039ΔpH_(i)/min±0.009 (n=52 cells/8 glands/5 animals). In the presence of100 μM histamine recovery rates were 0.042±0.007 ΔpH_(i)/min (n=64cells/8 glands/6 animals). In the presence of 100 μM acetylcholine F1glands alkalinized at a rate of 0.075±0.0015 ΔpH_(i)/min (n=86 cells/10glands/6 animals). In the presence of 100 μM pentagastrin F1 glands showalkalinization rates of 0.062±0.007 ΔpH_(i)/min (n=49 cells/6 glands/5animals).

FIGS. 10A-D shows original tracing of acid secretion comparing F1 glandsand Corpus glands with Omeprazole and AZD0865. Single rat gastric glandswere isolated, loaded with the pH sensitive dye BCECF to measureintracellular pH over single parietal cells and the pHi recovery ratewas calculated from the slope after an acid load using NH₄C1 prepulsetechnique as described previously. (A) Original tracing of anintracellular pH measurement demonstrating a F1 gland alkalinizationafter stimulation by histamine (100 μM). This tracing shows thatomeprazole (200 μM) does not inhibit acid secretion in F1 glands. (B)Corpus gland tracing of intracellular alkalinization after stimulationwith histamine (100 μM). This tracing shows that Omeprazole (200 μmolar)inhibits acid secretion in the corpus with a intracellularalkalinization rate of (0.014±0.002 ΔpH_(i)/min. (C) Intracellulartracing of pH measurements demonstrating that AZD0865 does notcompletely inhibit proton extrusion in the fundus as it does in thecorpus. In fundic glands which have been exposed to 10 μM of AZD0865 theintracellular recovery is 0.031±0.006 ΔpH_(i)/min. (D) In the corpusAZD0865 shows strong inhibition of potassium dependant recovery withintracellular alkalinization rates of 0.021±0.008 ΔpH_(i)/min.

BRIEF DESCRIPTION OF THE INVENTION

The present invention relates to novel compositions and methods for therapid inhibition of acid secretion that has little to no potential forside effects. In a first aspect, the present invention relates to zinccompositions comprising at least one pharmaceutically compatible zincsalt (preferably a water soluble salt) in an effective amount whichproduces a rapid decrease (i.e., within a period of no greater thanabout 5 minutes, no greater than about 10 minutes, no greater than about20 minutes, no greater than about 30 minutes, no greater than one hour)of acid secretion in a patient's stomach with a resulting increase(elevation) in stomach pH to an intragastric pH level of at least about3.0-3.5, at least about 4.0, about 4.0 to about 5.0. In this aspect ofthe invention, a patient who is in need of an increase of stomach pH istreated with an effective amount of a pharmaceutically compatible zincsalt such that rapid onset of elevated pH within the stomach occurs.This method invention relies on the administration (preferably by, butnot limited to, ingestion) of an effective amount of at least onepharmaceutically compatible, preferably water-soluble zinc salt and inwhich a substantial portion dissolves in the gastric juices at low pH(generally less than about 2.0) and preferably within a range pH fromlow pH (about 1.0 to about 2.0) to higher pH (about 5.5 to about 7.5 orhigher) such that effective amounts of zinc salt may be administered toprovide an initial rapid inhibition of acid release and a subsequentmaintenance of inhibition of acid release in the stomach. In the presentinvention, inhibition of gastric acid is inhibited preferably within arapid period of about 20 minutes to about 1 hour (generally, within aperiod no greater than about 5 minutes, within a period no greater thanabout 10 minutes or within a period no greater than about 20 minutes,within a period no greater than about 30 minutes, within a period nogreater than about one hour).

The rapid decrease of acid secretion in the patient's stomach occursthroughout the stomach (in both the upper stomach and lower stomachthrough inhibition of H⁺,K⁺-ATPase), although localized effects ofcompounds according to the present invention in the upper stomach,especially in the fundic region of the stomach (through inhibition of asecond distinguishable protein H⁺-ATPase) and/or the upper body of theupper stomach (through inhibition of H⁺,K⁺-ATPase). Thus, an additionalaspect of the invention is directed to the use of effective amounts ofpharmaceutically acceptable zinc compounds for the inhibition ofH⁺,K⁺-ATPase (generally throughout the stomach, H+-ATPase (primarily inthe fundic region of the stomach) and preferably both. The finding thatthe present compounds may be used to inhibit H⁺-ATPase in the fundicregion has important clinical ramifications for the following reasons:

1) The erosion of the esophagus by exposure to acid has life threateningconsequences due to either internal bleeding, ulceration, and or gastriccarcinoid formation by the prolonged exposure to acid. Pursuant to thepresent invention, as is now demonstrated—glands in the fundus are indirect proximity to the esophageal juncture, that they will secrete acidand can be inhibited by compounds according to the present invention,thus making the present compounds particularly effective in treatingGERD, NERD and related conditions.2) There is an ever increasing number of patients that are becominginsensitive to PPI (proton pump inhibitors) and have recurrent symptomsof acid reflux disease. The protein that we identified in the fundicglands is not sensitive to PPI's and could be the reason that thesepatients do not respond to classical therapy.3) Patients on PPI's for long periods of time appear to show some“rebound” acid secretion. This result could again be linked to thefundic H⁺-ATPase, which we show is sensitive to Histamine and to thelevels of protons within the cell.

In preferred embodiments of this invention aspect, a single zinc saltwhich is water-soluble regardless of pH (i.e., within a range of pH fromabout 1.0 to about 7.5 or above) is preferred. Zinc chloride is thepreferred salt for use in the present invention. In alternativeembodiments, a mixture of a low pH soluble zinc salt with a high pHsoluble zinc salt or a zinc salt which may be readily absorbed throughthe small intestine (such as a zinc amino acid chelate compound),optionally in combination with a pharmaceutically acceptable buffer isprovided. In this aspect of the invention, an effective amount of a zincsalt selected from the group consisting of zinc chloride (ZnCl₂), zincacetate, zinc ascorbate, zinc succinate, zinc tartrate, zinc malate,zinc maleate, a zinc amino acid chelate (mono- or bis-chelate) andmixtures thereof, preferably a mixture of zinc chloride and at least oneof zinc acetate, zinc gluconate, zinc succinate, zinc ascorbate, and azinc amino acid chelate is provided alone or in combination with apharmaceutically acceptable carrier, additive or excipient.

In various aspects, the present invention relates to the use of at leastone water-soluble zinc salt alone or in combination with at least onecompound/composition (within the context of the disease state orcondition to be treated) selected from the group consisting of atraditional proton pump inhibitor compound/composition, an H2 blocker,an antibiotic/antimicrobial agent (effective against H. pylori), acytoprotective agent or a mixture of these agents (Helidac, Prevpac) toprovide fast action in reducing gastric acid secretion, to lower the pHof the stomach, to prevent or reduce the likelihood of ulcer disease, totreat ulcer disease, to treat gastric cancer, to treat a disease orcondition selected from the group consisting of gastroesophageal refluxdisease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellisonsyndrome (ZE disease), ulcer disease, and gastric cancer, as well aspreventing or reducing the likelihood of ulcer disease.

Pharmaceutical compositions comprising a mixture of zinc salts whichmaximize both immediate and extended release characteristics of thepresent invention, optionally in combination with a pharmaceuticallyacceptable carrier, additive or excipient and further optionally aneffective amount of additional agent selected from the group consistingof a proton pump inhibitor, an H₂ blocker, an anti-H. pyloriantibiotic/antimicrobial, a cytoprotective agent and a combination ofagents, are additional aspects of the present invention. Any one or moreof these compositions may be used within context to treat the variousconditions/disease states as otherwise disclosed herein.

In an additional aspect of the present invention, pharmaceuticalcompositions comprise at least one water soluble zinc salt as otherwisedescribed herein in combination with at least one (additional)therapeutic agent wherein the oral administration of said agent isfavorably affected by elevated pH levels in the stomach, optionally incombination with a pharmaceutically acceptable carrier, additive orexcipient. It has unexpectedly been discovered that the inclusion of awater soluble zinc salt as otherwise described herein to raise the pH ofthe gastric juices, in combination with a therapeutic agent which isfavorably responsive to elevated pH levels because of the tendency ofthe agent to produce/increase undesired acidity in the stomach, becauseof acid sensitivity of the therapeutic agent, because of enhancedsolubility at higher acid pH's (less acid) of about 3.5-4.0 or higher,and/or because of the tendency of the therapeutic agent to create GItract distress or ulcerations at lower pH's, which are substantiallyreduced or alleviated at higher pH's represents a general approach forenhancing the oral administration of therapeutic agents by increasingbioavailability and/or decreasing the side effects from the therapeuticagent.

DETAILED DESCRIPTION OF THE INVENTION

The following terms are used throughout the specification to describethe present invention.

The term “patient” or “subject” refers to an animal, preferably amammal, even more preferably a human, in need of treatment or therapy towhich compounds according to the present invention are administered inorder to treat a condition or disease state treatable using compoundsaccording to the present invention. Depending upon the disease orcondition treated the term patient refers to the animal treated for thatdisease within context.

The term “effective” is used to describe a treatment, compound,composition, component or a related aspect of the present invention,which, when used in context, produces an intended result which mayinclude the increase in pH in the stomach, the reduction of symptomsassociated with excess acid release, the enhanced bioavailability of anadministered compound, or the favorable treatment of a disease state orcondition. The term effective subsumes both an amount or concentrationof one or more active agent(s) as described herein and a period of timewhich is consistent with producing an intended effect.

The term “pharmaceutically acceptable zinc salt” or zinc salt” used incontext, refers \ to a salt or salt combination which contains zinc,dissolves in the gastric juices at reduced pH and is absorbed to someextent in the gastric mucosa at a low pH of about 2 or less, at a higherpH of about 4.0 to 5.0 or above of the stomach and at the high pH's ofthe small intestine to reach and maintain effective concentrations ofzinc in the blood stream over a period of therapy. Exemplarypharmaceutically compatible zinc salts include both inorganic andorganic zinc salts, for example, zinc acetate, zinc ascorbate, zincbenzoate, zinc bromide, zinc butyrate, zinc caprylate, zinc carbonate(soluble in dilute acid at low pH of the stomach), zinc carnosine, zinccitrate, zinc chloride, zinc fluoride, zinc formate, zinc fumarate, zincfumaric acid monoethyl ester, zinc gallate, zinc gluconate, zincglutarate, zinc glycerate, zinc glycerophosphate, zinc glycolate, zinchydroxide, zinc iodide, zinc iodate, zinc lactate, zinc malate, zincmaleate, zinc myristate, zinc nitrate, zinc oratate, zinc oxide, zincphenol sulfonate, zinc phosphate, zinc picolinate, zinc picrate, zincpropionate, zinc salicylate, zinc selenate, zinc stearate, zincsuccinate, zinc sulfate, zinc tannate, zinc tartrate, zinc undecylenate,zinc valerate, and zinc chelates, including zinc amino acid chelates(including, depending on concentration, mono- and bis-chelates of L- orD-amino acids (preferably, the naturally occurring L-amino acid whichmay be more readily absorbed from the gastrointestinal tract) whichcomplex or chelate with zinc including preferably, L-arginine (zincarginate), L-cysteine, L-cystine, L-N-acetylcysteine, L-histidine (alsoD-histidine as zinc histidinate), L-taurine, L-glycinate, L-aspartate(zinc aspartate) and L-methionine (zinc methionine), among others. Notethat for purposes of the present invention, zinc chelates, includingzinc nicotinamide complex and zinc amino acid chelates are consideredzinc salts. Preferred zinc salts for use in the present inventioninclude zinc acetate, zinc arginate, zinc butyrate, zinc chloride, zinccitrate, zinc formate, zinc fumarate, zinc gluconate, zinc glutarate,zinc glycerate, zinc glycolate, zinc histidinate, zinc lactate, zincmalate, zinc maleate, zinc picolinate, zinc propionate, zinc salicylate,zinc succinate, zinc sulfate, zinc undecylenate, zinc salt of 1,6fluctose diphosphate and mixtures thereof.

Preferably, the pharmaceutically acceptable zinc salt is “watersoluble”. The term “water soluble” is used to describe a zinc salt (andzinc chelates which fall under this term) according to the presentinvention which has a water solubility of at least about 0.01moles/Liter, preferably at least about 0.05 moles/Liter.

One of ordinary skill will recognize favorable zinc salts to use in thepresent invention. In aspects of the invention, at least onepharmaceutically compatible, water-soluble zinc salt is administered toa patient in order to provide a rapid inhibition of acid release in thestomach, resulting in an increase in stomach pH to above 4 (generallybetween about 4.0 and 5.0, in some cases above 5.0) for an extendedperiod of time, preferably at least 2 hours, 4 hours, 6 hours, 8 hours,10 hours, 12 hours, 16 hours, 20 hours or more. It is noted that incertain preferred aspects of the invention, the zinc salt or combinationof salts chosen to be administered to the patient may be adjusted toprovide an initial bolus concentration of zinc in the stomach at low pHin order to produce the rapid inhibition of acid release and rise in pHin the stomach to a level above about 4. In addition, a preferred zincsalt or salt combination inhibits acid release in the stomach at varyinglevels of acidity and pH—i.e., at a level which is quit acidic (pH, lessthan about 2.0) to a pH of about 4.0 or higher.

The term “providing fast action in reducing gastric acid secretion” isused to describe the fact that the method according to the presentinvention results in an increase in pH to a level of at least about 4.0,more preferably about 4.0 to about 5.0 or slightly above, in a period ofno greater than about 30 minutes, preferably in less than about 20-30minutes, even more preferably in less than about 10-20 minutes, in about15 minutes or less or alternatively, in less than about 5 minutes.

The term “secretagogue” refers to the period during which time thepariental cells of the stomach secrete acid into the gastric juices tolower pH. Often the secretagogue period occurs just after a meal, butthe secretion of acid may occur at other times. The secretagogue phasecan be of short duration or longer duration.

The term gastroesophageal reflux disease or “GERD” or “acid reflux” is acondition in which the liquid content of the stomach regurgitates (backsup, or refluxes) into the esophagus. The liquid can inflame and damagethe lining of the esophagus although this occurs in a minority ofpatients. The regurgitated liquid usually contains acid and pepsin thatare produced by the stomach. The refluxed liquid also may contain bilethat has backed-up into the stomach from the duodenum. Acid is believedto be the most injurious component of the refluxed liquid. Pepsin andbile also may injure the esophagus, but their role in the production ofesophageal inflammation and damage (esophagitis) is not as clear as isthe role of acid.

GERD is a chronic condition. Once it begins, it usually is life-long. Ifthere is injury to the lining of the esophagus (esophagitis), this alsois a chronic condition. Moreover, after the esophagus has healed withtreatment and treatment is stopped, the injury will return in mostpatients within a few months. Once treatment for GERD is begun,therefore, it may be necessary to continue the treatment continually,generally for short periods of time.

Actually, the reflux of the stomach's liquid contents into the esophagusoccurs in most normal individuals. In fact, one study found that refluxoccurs as frequently in normal individuals as in patients with GERD. Inpatients with GERD, however, the refluxed liquid contains acid moreoften, and the acid remains in the esophagus longer.

Gravity, swallowing, and saliva are important protective mechanisms forthe esophagus, but they are effective only when individuals are in theupright position. At night while sleeping, gravity is not in effect,swallowing stops, and the secretion of saliva is reduced. Therefore,reflux that occurs at night is more likely to result in acid remainingin the esophagus longer and causing greater damage to the esophagus.

Certain conditions make a person susceptible to GERD. For example,reflux can be a serious problem during pregnancy. The elevated hormonelevels of pregnancy probably cause reflux by lowering the pressure inthe lower esophageal sphincter (see below). At the same time, thegrowing fetus increases the pressure in the abdomen. Both of theseeffects would be expected to increase reflux. Also, patients withdiseases that weaken the esophageal muscles (see below), such asscleroderma or mixed connective tissue diseases, are more prone todevelop reflux.

The cause of GERD is complex. There probably are multiple causes, anddifferent causes may be operative in different individuals or even inthe same individual at various times. A number of patients with GERDproduce abnormally large amounts of acid, but this is uncommon and not acontributing factor in the vast majority of patients. The factors thatcontribute to causing GERD are the lower esophageal sphincter, hiatalhernias, esophageal contractions, and emptying of the stomach.Notwithstanding the cause of GERD, the present invention may reduce thetendency of having injurious acid reflux into the esophagus, causingdamage.

When the wave of contraction in the esophagus is defective, refluxedacid is not pushed back into the stomach. In patients with GERD, severalabnormalities of contraction have been described. For example, waves ofcontraction may not begin after each swallow or the waves of contractionmay die out before they reach the stomach. Also, the pressure generatedby the contractions may be too weak to push the acid back into thestomach. Such abnormalities of contraction, which reduce the clearanceof acid from the esophagus, are found frequently in patients with GERD.In fact, they are found most frequently in those patients with the mostsevere GERD. The effects of abnormal esophageal contractions would beexpected to be worse at night when gravity is not helping to returnrefluxed acid to the stomach. Note that smoking also substantiallyreduces the clearance of acid from the esophagus. This effect continuesfor at least 6 hours after the last cigarette.

Most reflux during the day occurs after meals. This reflux probably isdue to transient LES relaxations that are caused by distention of thestomach with food. A minority of patients with GERD, about 20%, has beenfound to have stomachs that empty abnormally slowly after a meal. Theslower emptying of the stomach prolongs the distention of the stomachwith food after meals. Therefore, the slower emptying prolongs theperiod of time during which reflux is more likely to occur.

The term “non-erosive reflux disease” or “NERD” is used describe aspecific form of GERD, described above. In some cases, GERD erodes theesophageal lining, creating a condition called esophagitis. NERD is GERDthat does not cause esophagitis. Because most GERD sufferers do not haveesophagitis, NERD is the most common form of GERD. Because its namecontains the word “nonerosive,” it may appear that NERD is the leastsevere form of GERD, but this is not necessarily so. NERD is actuallymore likely to produce extra-esophageal complications, and is also lesslikely to respond to fundoplication surgery. In one study, only 56% ofNERD patients (compared with 90% of patients with erosive reflux)reported that their symptoms were completely eliminated withfundoplication. NERD was also twice as likely to cause swallowingdifficulties.

Heartburn is the chief symptom of NERD. It has a number of potentialcauses, including hiatal hernia, lifestyle behaviors, and diet. Manypeople deal with heartburn by simply adjusting their behavior. In somecases, medication or surgery may be required. Traditional antacids havealso been used to treat NERD.

The term “Zollinger-Ellison syndrome” or “ZE syndrome” is usedthroughout the specification to describe a condition caused by abnormalproduction of the hormone gastrin. In ZE syndrome, small tumor(gastinoma) in the pancreas or small intestine produces the high levelsof gastrin in the blood. ZE syndrome is caused by tumors usually foundin the head of the pancreas and the upper small bowel. These tumorsproduce the hormone gastrin and are called gastrinomas. High levels ofgastrin cause overproduction of stomach acid. High stomach acid levelslead to multiple ulcers in the stomach and small bowel. Patients with ZEsyndrome may experience abdominal pain and diarrhea. The diagnosis isalso suspected in patients without symptoms who have severe ulcerationof the stomach and small bowel.

The agents of choice for treating ZE syndrome are the proton pumpinhibitors (PPI) as described hereinabove. These drugs dramaticallyreduce acid production by the stomach, and promote healing of ulcers inthe stomach and small bowel. They also provide relief of abdominal painand diarrhea.

Surgical removal of a single gastrinoma may be attempted if there is noevidence that it has spread to other organs (such as lymph nodes or theliver). Surgery on the stomach (gastrectomy) to control acid productionis rarely necessary today. Early diagnosis and surgical removal of thetumor is associated with a cure rate of only 20% to 25%. However,gastrinomas grow slowly, and patients may live for many years after thetumor is discovered. Acid-suppressing medications are very effective atcontrolling the symptoms of acid overproduction.

The term “ulcer” is used throughout the specification to describe anarea of tissue erosion, for example, especially of the lining of thegastrointestinal (GI) tract, especially of the stomach (peptic ulcer),esophagus or small intestine (duodenal ulcer). Due to the erosion, anulcer is concave. It is always depressed below the level of thesurrounding tissue. Ulcers can have diverse causes, but in the GI tract,they are believed to be primarily due to infection with the bacteria H.pyloridus (h. pylori). GI ulcers, however, may be made worse by stress,smoking and other noninfectious factors, especially including excessivestomach acid because a lower pH tends to be a better growth environmentfor H. Pyloridus.

Traditional treatments for H. pyloridus infections includeantimicrobials/antibiotics, such as amoxicillin, clarithromycin(biaxin), metronidazole (flagyl) and tetracycline (“an anti-H. pyloriagent”); H₂-blockers, such as cimetidine (tagamet), famotidine (pepcid),nizatidine (axid), ranitidine (zantac); proton pump inhibitors (PPI),such as esomeprazole (nexium), lansoprazole (prevacid), omeprazole(prilosec), pantoprazole (protonix) and rabeprazole (aciphex);cytoprotective agents, such as bismuth subsalicylate, sucralfate; andcombination agents, such as Helidac (bismuth subsalicylate,metronidazole, and tetracycline combination), Prevpac (lansoprazole,clarithromycin and amoxicillin).

The present invention may be used to treat an H. pyloridus infection ina patient by administering an effective amount of at least onepharmaceutically acceptable water-soluble zinc salt, either alone or incombination (preferably, by coadministration) with at least one other ofthe traditional treatment modalities, as described above.

The term “coadministration” or “combination therapy” is used to describea therapy in which at least two active compounds in effective amountsare used to treat one or more of the disease states or conditions asotherwise described herein at the same time. Although the termcoadministration preferably includes the administration of two activecompounds to the patient at the same time, it is not necessary that thecompounds be administered to the patient at the same time, althougheffective amounts of the individual compounds will be present in thepatient at the same time. The active compositions may include one ormore zinc salts and/or additional compounds/compositions such as protonpump inhibitors, H₂ blockers, antibiotics/antimicrobial agents,cytoprotective agents or combination agents as otherwise describedherein in effective amounts for the disease or condition for which thecompounds are typically used. In addition, coadministration alsocontemplates combinations of water soluble zinc salts as otherwisedescribed herein in combination with at least one therapeutic agentwherein elevated pH levels provide a favorably response to theadministration of said therapeutic agent.

The term “favorably responsive to elevated pH levels” or “favorablyorally administered” is used to describe therapeutic agents which, inorally administered compositions, provide a favorable response to anelevated pH in the stomach produced by a water soluble zinc saltaccording to the present invention, whether that favorable response is areduction in gastric irritation from the therapeutic agent, a reductionin acid generation/production in the stomach by the therapeutic agent,to increase bioavailability which is negatively impacted by thesensitivity and/or inactivation of the therapeutic agent to an acidicenvironment or because of increased solubility of the therapeutic agentin gastric juices at high pH levels. It has unexpectedly been discoveredthat the inclusion of a water soluble zinc salt as otherwise describedherein, in combination with a therapeutic agent which is favorablyresponsive to elevated pH levels because of the tendency of the agent toincrease acid release and a lowering of pH in the stomach, because ofincreased acid sensitivity of the therapeutic agent, because of enhancedsolubility of the agent (with concombinant increased bioavailability ofthe therapeutic agent) at higher (less acid) pH's of about 3.5-4.0 orhigher, and/or because of the tendency of the therapeutic agent tocreate GI tract distress or ulcerations at lower pH's, which aresubstantially reduced or alleviated at higher pH's results in greateractivity and/or fewer side effects from the therapeutic agent.

In general, the weight ratio of water soluble zinc salt to therapeuticagent which is included in combination therapeutic compositionsaccording to the present invention ranges from about 1:20 to about 20:1,about 1:10 to about 10:1, about 1:5 to about 5:1, about 1:3 to about3:1, about 1:2 to about 2:1, about 1:1.5 to about 1.5 to 1, about 1:1.Of course, the weight ratio used in a particular combinationpharmaceutical composition will depend upon the water solubility of thezinc salt and the activity of the therapeutic agent in producing a sideeffect (such as increasing stomach acid or increasing gastrointestinaldistress (GI tract distress) or the tendency to increase the environmentfor ulceration in the gastrointestinal tract), or to be inactivated,rendered insoluble or have its bioavailability negatively impacted bystomach acid, etc.

Therapeutic compounds which may be favorably administered orally (forthe reasons which are outlined above) in combination with a watersoluble zinc salt in the present invention include the following:

Chemotherapeutic Agents

Zn plus chemolitic agents for use in treating intestinal cancer

e.g., Cysplatine;

Zn plus chemolitic agents used to treat whole tissue cancer withsecondary complications in the intestinal track (GI tract distress) asfollows:

13-cis-Retinoic Acid;

2-CdA (2-Chlorodeoxyadenosine);

5-Azacitidine;

5-Fluorouracil (5-FU);

6-Mercaptopurine (6-MP);

6-TG (6-Thioguanine);

Abraxane;

Accutane® (Isotretinoin);

Actinomycin-D;

Adriamycin® (Doxorubicin Hydrochloride);

Adrucil® (Fluorouracil);

Agrylin® (Anagrelide;

Ala-Cort® (Hydrocortisone);

Aldesleukin;

Alemtuzumab;

ALIMTA (Pemetrexed);

Alitretinoin;

Alkaban-AQ® (Vinblastine);

Alkeran® (Melphalan);

All-transretinoic Acid;

Alpha Interferon;

Altretamine;

Amethopterin;

Amifostine;

Aminoglutethimide;

Anagrelide;

Kidrolase® (Asparaginase);

Lanacort® (Hydrocortone Phosphate);

L-asparaginase;

LCR (Leurocristine);

Lenalidomide;

Letrozole;

Leucovorin;

Leukeran;

Leukine™ (Sargramostim);

Leuprolide;

Leurocristine;

Leustatin™ (Cladribin);

Liposomal Ara-C;

Liquid Pred® (Deltasone);

Lomustine;

L-PAM (L-phenylalanine mustard, phenylalanine mustard);

L-Sarcolysin;

Lupron® (Leuprolide Acetate Inj);

Lupron Depot® (Leuploride Acetate);

Matulane® (Procarbazine);

Maxidex;

Mechlorethamine;

Mechlorethamine Hydrochloride;

Medralone® (Methylprednisolone);

Medrol® (Methylprednisolone);

Megace® (Megestrol Acetate);

Megestrol;

Megestrol Acetate;

Melphalan;

Mercaptopurine;

Mesna;

Mesnex™ (Mesna);

Methotrexate;

Anandron® (Nilutamide);

Anastrozole

Arabinosylcytosine;

Ara-C;

Aranesp® (Darbepoetin Alfa);

Aredia® (Pamidronate);

Arimidex® (Anastrozole);

Aromasin® (Exemestane);

Arranon® (Nelarabine);

Arsenic Trioxide;

Asparaginase;

ATRA (Atragen);

Avastin® (Bevacizumab);

Azacitidine;

BCG (Bacillus Calmette Guerin);

BCNU (Carmustine);

Bevacizumab;

Bexarotene;

BEXXAR® (Tositumomab and Iodine 1131 Tositumomab);

Bicalutamide;

BiCNU (CARMUSTINE);

Blenoxane® (Bleomycin Sulfate);

Bleomycin;

Bortezomib;

Busulfan;

Busulfex® (Busuflan);

C225 (Eribitux);

Calcium Leucovorin;

Campath® (Alemtuzumab;

Camptosar® (Irinotecan hydrochloride);

Camptothecin-11;

Capecitabine;

Carac™ (Fluorouracil);

Carboplatin;

Carmustine;

Carmustine Wafer;

Casodex® (Bicalutamide);

CC-5013 (Revlimid);

CCNU (lomustine);

CDDP (Cisplatin);

CeeNU;

Cerubidine® (Daunorubicin);

Cetuximab;

Chlorambucil;

Cisplatin;

Methotrexate Sodium;

Methylprednisolone;

Meticorten® (prednisone);

Mitomycin;

Mitomycin-C;

Mitoxantrone;

M-Prednisol® (Methlyprednisolone);

MTC (Mitomycin);

MTX (Methotrexate);

Mustargen® (Mechlorethamine HCl);

Mustine;

Mutamycin® (Mitomycin);

Myleran® (Busulfan);

Mylocel™ (Hydroxyurea);

Mylotarg® (Gemtuzumab Ozogamicin);

Navelbine® (Vinorelbine Tartrate);

Nelarabine

Neosar® (Cyclophosphamide);

Neulasta™ (Pegfilgrastim);

Neumega® (Oprelvekin);

Neupogen® (Filgrastim);

Nexavar® (Sorafenib);

Nilandron® (Nilutamide);

Nilutamide;

Nipent® (Pentostatin);

Nitrogen Mustard;

Novaldex® (Genox);

Novantrone® (Mitoxantrone);

Octreotide;

Octreotide acetate;

Oncospar® (Pegylated asparaginase);

Oncovin® (Vincristine Sulfate);

Ontak® (Denileukin Diftitox);

Onxal™ (Paclitaxel);

Oprevelkin;

Orapred® (Prednisolone Sodium Phosphate);

Orasone® (prednisone);

Oxaliplatin;

Paclitaxel;

Paclitaxel Protein-bound;

Pamidronate;

Panitumumab;

Panretin® (Alitretinoin);

Paraplatin® (Paraplatin);

Citrovorum Factor;

Cladribine;

Cortisone;

Cosmegen® (Dactinomycin);

CPT-11 (Topotecan);

Cyclophosphamide;

Cytadren® (Aminoglutethimide);

Cytarabine;

Cytarabine Liposomal;

Cytosar-U® (Cytarabine);

Cytoxan® (Cyclophosphamide);

Dacarbazine;

Dacogen;

Dactinomycin;

Darbepoetin Alfa;

Dasatinib;

Daunomycin;

Daunorubicin;

Daunorubicin Hydrochloride;

Daunorubicin Liposomal;

DaunoXome® (Daunorubicin Liposoma);

Decadron;

Decitabine;

Delta-Cortef® (Prednisolone);

Deltasone® (Prednisone);

Denileukin diftitox;

DepoCyt™ (Cytarabine liposome injection);

Dexamethasone;

Dexamethasone acetate;

Dexamethasone Sodium Phosphate;

Dexasone;

Dexrazoxane;

DHAD (Novantrone);

DIC (Disseminated intravascular coagulation);

Diodex;

Docetaxel;

Doxil® (Doxorubicin HCl liposome);

Doxorubicin;

Doxorubicin liposomal;

Droxia™ (Hydroxyurea);

DTIC (Dacarbazine);

DTIC-Dome® (dacarbazine);

Duralone®;

Efudex® (fluorouracil topical);

Eligard™ (Leuprolide Acetate);

Pediapred® (Prednisolone Sodium);

PEG Interferon;

Pegaspargase;

Pegfilgrastim;

PEG-INTRON™ (Peginterferon alfa-2b);

PEG-L-asparaginase;

PEMETREXED;

Pentostatin;

Phenylalanine Mustard;

Platinol® (Cisplatin);

Platinol-AQ® (Cisplatin);

Prednisolone;

Prednisone;

Prelone® (Prednisolone);

Procarbazine;

PROCRIT® (Epoetin Alfa);

Proleukin® (Aldesleukin);

Prolifeprospan 20 with Carmustine;

Implant;

Purinethol® (Mercaptopurine);

Raloxifene;

Revlimid® (Lenalidomide);

Rheumatrex® (Trexall);

Rituxan® (Rituximab);

Rituximab;

Roferon-A® (Interferon Alfa-2a);

Rubex® (adriamycin)

Rubidomycin hydrochloride;

Sandostatin® (Octreotide Acetate);

Sandostatin LAR® (Octreotide Acetate inj);

Sargramostim;

Solu-Cortef® (Hydrocortisone Sodium Succinate);

Solu-Medrol® (Methylprednisolone sodium succinate);

Sorafenib;

SPRYCEL™ (Dasatinib);

STI-571 (Gleevec);

Streptozocin;

SU11248;

Sunitinib;

Sutent® (Sunitinib Malate);

Tamoxifen;

Tarceva® (Erlotinib);

Targretin® (Bexarotene);

Taxol® (Paclitaxel);

Ellence™ (Epirubicin hydrochloride);

Eloxatin™ (Oxaliplatin Inj);

Elspar® (Asparaginase);

Emcyt® (Estramustine);

Epirubicin;

Epoetin alfa;

Erbitux™ (Cetuximab);

Erlotinib;

Erwinia L-asparaginase;

Estramustine;

Ethyol;

Etopophos® (Etoposide Phosphate);

Etoposide;

Etoposide Phosphate;

Eulexin® (Flutamide);

Evista® (Raloxifene);

Exemestane;

Fareston® (Toremifene);

Faslodex® (Fulvestrant);

Femara® (Letrozole);

Filgrastim;

Floxuridine;

Fludara® (Fludarabine);

Fludarabine;

Fluoroplex® (Fluorouracil topical);

Fluorouracil;

Fluorouracil (cream);

Fluoxymesterone;

Flutamide;

Folinic Acid;

FUDR® (Floxuridine);

Fulvestrant;

G-CSF (Neupogen);

Gefitinib;

Gemcitabine;

Gemtuzumab ozogamicin;

Gemzar® (Gemcitabine);

Gleevec™;

Gliadel® (Carmustine Wafer);

GM-CSF;

Goserelin;

Granulocyte—Colony Stimulating Factor;

Granulocyte Macrophage Colony Stimulating Factor;

Taxotere® (Docetaxel);

Temodar® (Temozolomide);

Temozolomide;

Teniposide;

TESPA (Thiotepa);

Thalidomide;

Thalomid® (Thalidomide);

TheraCys® (Intravesical);

Thioguanine;

Thioguanine Tabloid® (Thioguanine);

Thiophosphoamide;

Thioplex® (Thiotepa);

Thiotepa;

TICE® (Bacillus of Calmette and Guerin);

Toposar® (Etoposide);

Topotecan;

Toremifene;

Tositumomab;

Trastuzumab;

Tretinoin;

Trexall™ (Methotrexate);

Trisenox® (Arsenic);

TSPA (Thiotepa);

VCR;

Vectibix™ (Panitumumab);

Velban® (Vinblastine Sulfate);

Velcade® (Bortezomib);

VePesid® (Etoposide);

Vesanoid® (Tretinoin);

Viadur™ (Leuprolide Acetate Implant);

Vidaza® (Azacitidine);

Vinblastine;

Vinblastine Sulfate;

Vincasar Pfs® (Vincristine Sulfate Injection);

Vincristine;

Vinorelbine;

Vinorelbine tartrate;

VLB (Vinblastine Sulfate);

VM-26;

Vorinostat;

VP-16 (Etoposide);

Vumon® (Teniposide);

Xeloda® (Capecitabine);

Zanosar® (Streptozocin);

Halotestin® (Fluoxymesterone);

Herceptin® (Trastuzumab);

Hexadrol;

Hexalen® (Altretamin);

Hexamethylmelamine;

HMM (antineoplastic or cytotoxic);

Hycamtin® (Hycamtin);

Hydrea® (Hydroxyurea);

Hydrocort Acetate® (Hydrocortisone);

Hydrocortisone;

Hydrocortisone Sodium Phosphate;

Hydrocortisone Sodium Succinate;

Hydrocortone Phosphate;

Hydroxyurea;

Ibritumomab;

Ibritumomab Tiuxetan;

Idamycin® (Idarubicin);

Idarubicin;

Ifex® (Ifosfamide);

IFN-alpha;

Ifosfamide;

IL-11;

IL-2;

Imatinib mesylate;

Imidazole Carboxamide;

Interferon alfa;

Interferon Alfa-2b (PEG Conjugate);

Interleukin-2;

Interleukin-11;

Intron A® (interferon alfa-2b);

Iressa® (Getfitinib);

Irinotecan;

Isotretinoin;

Zevalin™;

Zinecard® (Dexrazoxane);

Zoladex® (Goserelin);

Zoledronic acid;

Zolinza;

Zometa® (Zoledronic Acid for Inj).

Immunosuppression Agents

Zn plus agents used as immunosuppressive agents following organtransplantation such as cyclosporine and its derivatives, azathioprine,6-mercaptopurine, Prednisone, infliximab (Remicade), and tetracycline,among others.

Assorted Medications

Zn given in combination with asthma related drugs: Theophylline andcortisteroids, including betamethasone, cortisone, dexamethasone,hydrocortisone, methylprednisolone, prednisolone and budenoise. Each ofthese agents can induce stomach lining erosion and increased acidsecretion.

NSAIDS:

Over the counter NSAIDS and associated compounds cause GERD and GERDsymptoms including ulcer disease:

OTC Name Generic Name Actron ® ketoprofen Advil ® ibuprofen Aleve ®naproxen sodium Bayer ® aspirin Ecotrin ® aspirin Excedrin ® aspirin,acetaminophen and caffeine Motrin IB ® ibuprofen Nuprin ® ibuprofenOrudis KT ® ketoprofen

Antidepressive Agents

Selective serotonin reuptake inhibitors (SSRIs): Citalopram (Celexa),Escitalopram (Lexapro), Fluoxetine (Prozac); Parozxetine (Paxel) andSertraline (Zoloft.)

Zn taken in combination with the following drugs could potentiallyincrease bioavailability of molecule due to the fact zinc does not causethe effects on inhibiting Cytochromes P-450 2C9 & 3A4 as omeprazole oresoprazole.

-   -   Carbamazepine;    -   Cyclosporine;    -   Diazepam, other benzodiazepines;    -   Diltiazem, Nifedipine, Verapamil;    -   Erythromycin, Clarithromycin;    -   Lidocaine;    -   Lovastatin, other statins including Atorvastatin,    -   Phenytoin;    -   Quinidine;    -   Terfenadine

The term “proton pump inhibitor” is used throughout the specification todescribe Proton pump inhibitors as drugs that help control the painfuldiscomfort of heartburn and gastroesophageal reflux disease (GERD), andpromote the healing of stomach and duodenal ulcers. Proton pumpinhibitors are only available by prescription. They come as tablets,capsules, injections, or powders that are made into a suspension.

Proton inhibitors work by blocking the production of stomach acid. Theyinhibit a system in the stomach known as the proton pump, which isanother name for the “hydrogen-potassium adenosine triphosphate enzyme”system. Proton pump inhibitors are rather versatile. They are used toheal stomach and duodenal ulcers, including stomach ulcers caused bytaking nonsteroidal anti-inflammatory drugs. They are also used torelieve symptoms of oesophagitis (inflammation of the oesophagus orgullet) and severe gastroesophageal reflux (GERD), as discussed above.

Combined with certain antibiotics (such as amoxycillin andclarithromycin) or with zinc salts according to the present invention,proton pump inhibitors are effective for treating Helicobacter pyloriinfections (a bacterial infection of the stomach). The H. pyloribacterium is a chief suspect in the cause of recurring stomach ulcers.PPIs are also a first-choice treatment for the rare condition calledZollinger-Ellison syndrome, discussed above.

Proton Pump Inhibitors exhibit side effects, although they tend to bemanageable, including diarrhea, feeling or being sick, constipation,flatulence, abdominal pain, headaches and more rarely, allergicreactions, itching, dizziness, swollen ankles, muscle and joint pain,blurred vision, depression and dry mouth, among others. Long-term use ofproton pump inhibitors can result in stomach infections. Because protonpump inhibitors completely stop acid production—and stomach acid helpskill microbes such as bacteria in the stomach—using PPIs can lead togrowth of potentially harmful microbes in the stomach.

Proton pump inhibitors exhibit significant, sometimes deleterious druginteractions, including reactions with phenytoin as an epilepsy agentand warfarin to prevent blood clots, to increase their effects, withketoconazole and itraconazole to reduce their absorptivity, withdiazepam (valium) to decrease its metabolism.

Proton pump inhibitors are usually taken for 1-2 months, but in somecases may be taken longer. Symptoms may return when a person stopstaking a proton pump inhibitor. Proton pump inhibitors may causeinternal bleeding, signs of which include vomiting blood, detecting asubstance-like coffee grounds in your vomit, or pass black tarry stools,see your doctor immediately.

Common proton pump inhibitors include omeprazole (Prilosec),esomeprazole (Nexium), lansoprazole (Prevacid), pantoprazole (Protonix)and rabeprazole sodium (Aciphex).

The present invention relates to a method for providing fast action withoptional long duration effect in reducing gastric acid secretion,raising the pH of the stomach during a resting phase, decreasing theduration of stomach acid release during a secretagogue phase and fortreating conditions including gastroesophageal reflux disease (GERD),non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZEdisease), ulcer disease, and gastric cancer where the reduction ingastric acid secretion is beneficial, as well as preventing or reducingthe likelihood of ulcer disease by reducing gastric acid section. Inaddition, the present methods are useful for treating patients who arenon-responsive to proton pump inhibitors (PPI) and as an alternative totraditional therapies or conditions which are caused by rapid andcomplete inhibition of secretagogue induced acid secretion.

The method comprises administering an effective amount of at least onepharmaceutically acceptable water-soluble zinc salt to alleviate ortreat the condition or disease state. The methods may involve theadministration of a water-soluble zinc salt alone or in combination withother agents as disclosed herein a single time, or preferably for longerduration, usually about 2-3 days to about 2-3 months, with varyingintervals in between, depending upon the prognosis and outcome of thetreatment.

Zinc salts according to the present invention may be administered aloneor in combination with other compounds, compositions or therapies,depending upon the condition or disease state to be treated, includingan effective amount of a proton pump inhibitor or other agent asotherwise described herein which may be used to treat H. pyloriinfections. These agents include proton pump inhibitors such asesomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole, H2blockers such as cimetidine, famotidine, nizatidine or ranitidine,anti-H. pylori agents, such amoxicillin, clarithromycin (biaxin),metronidazole (flagyl) or tetracycline, cytoprotective agents such asbismuth subsalicylate or sucralfate, or a combination agent such asHelidac or Prevpac.

In a preferred aspect of the invention, at least one water-soluble zincsalt is used wherein the zinc salt or combination is characterized asbeing soluble and absorbable (through the gastrointestinal mucosa) atboth low pH (i.e., a pH of about 1-2, which occurs in an acidiccondition in the stomach) and higher pH (i.e., a pH of about 4-5 orslightly above after acid secretion in the stomach is inhibited or evenhigher—i.e., a pH of about 5.5-6.0 in the duodenum to about 6.5-7.5 inthe jejunum and ileum—the pH is slightly higher in the ileum than in thejejunum). By providing for compositions which are both water-soluble andabsorbable throughout the gastrointestinal mucosa (i.e. in the stomachand through the various sections of the small intestine), thebioavailability of the zinc salt will be maximized as will favorabletherapy of the conditions or disease states to be treated. In thisaspect, a preferred combination of effective amounts of zinc chlorideand at least one zinc salt preferably selected from the group consistingof zinc acetate, zinc arginate, zinc butyrate, zinc citrate, zincformate, zinc fumarate, zinc gluconate, zinc glutarate, zinc glycerate,zinc glycolate, zinc histidinate, zinc lactate, zinc malate, zincmaleate, zinc picolinate, zinc propionate, zinc salicylate, zincsuccinate, zinc sulfate, zinc undecylenate, zinc salt of 1,6 fluctosediphosphate and mixtures thereof, more preferably, zinc acetate, zincgluconate, zinc ascorbate, zinc succinate and a zinc amino acid chelate(as mono- or bis-amino acid chelate) is preferred, although numerousother zinc acid compounds may be combined to produce favorable results.

Preferred zinc salts include those salts in which the anionic counterionin protonated form has a pKa of at least about 4 to about 5.5 or higher.Mixtures of zinc salts wherein all of the zinc salts are soluble withina range of pH from 1-2 to about 7.5 are preferred. Zinc acetate, zincgluconate, zinc glycolate, zinc succinate and zinc ascorbate alone or incombination with another zinc salt, especially zinc chloride, areparticularly useful for use in the present invention. Zinc chelates,especially zinc amino acid chelates (mono- or bis-amino acid chelates)may also be preferably used wherein a combination of zinc chloride and azinc amino acid chelate selected from the group consisting of zincchelates (mono- or bis-chelates) of L-cysteine, L-cystine,L-N-acetylcysteine, L-histidine, D-histidine, L-taurine, L-glycinate,L-aspartate, L-methionine, and mixtures thereof.

Note that the following zinc salts have solubilities which tend to bereduced at pH values above about 7.0, so approaches to formulationshould accommodate such information where absorptivity from the smallintestine is featured (duodenum, jejunum and ileum), especially at thedistil end (jejunum, ileum) where the pH of the small intestine may riseto between 7-8.0. Note that the use of such salts may favorablyinfluence release characteristics of formulations and provide a means ofdelivering therapeutic agents, especially those which are administeredin combination therapy according to the present invention. Zinc saltsthat become insoluble above a pH of 7 include zinc acetate, zincchloride, zinc bromide, zinc fluoride, zinc iodide, zinc sulfate, zinccitrate, zinc lactate, zinc nitrate, zinc propionate, zinc salicylate,zinc tartrate, zinc valerate, zinc gluconate, zinc selenate, zincbenzoate, zinc formate, zinc glycerophosphate, zinc picrate, zincbutyrate, and the like, and combinations thereof.

Preferred zinc salts according to the invention include zinc chloride(where pKa of the counterion is not important because of its interactionwith chloride channels) and organic acids including zinc acetate (pka4.75), zinc gluconate, zinc succinate, zinc tartrate, zinc malate, zincmaleate, zinc zinc ascorbate (pka of 4.2 and 11.6). Other zinc salts oforganic acids may also be preferred, depending on context of use. Inaddition, zinc glycolate and zinc lactate may also be used preferably,zinc glycolate being preferred. Other preferred salts include, forexample, zinc acetate, zinc arginate, zinc butyrate, zinc chloride, zinccitrate, zinc formate, zinc fumarate, zinc gluconate, zinc glutarate,zinc glycerate, zinc glycolate, zinc histidinate, zinc lactate, zincmalate, zinc maleate, zinc picolinate, zinc propionate, zinc salicylate,zinc succinate, zinc sulfate, zinc undecylenate, zinc salt of 1,6fluctose diphosphate and mixtures thereof. In aspects of the invention,it is preferred that when a combination of zinc salts is used that atleast one zinc salt which is effective at low pH in the stomach (forimmediate inhibition of acid secretion) be combined with an agent whichmay exhibit a heightened effect in the stomach at a pH of 4.0-5.0 orhigher, or which is preferentially absorbed in the small intestine (azinc mono- or bis-amino acid chelate or other chelate).

While not being limited by way of theory, it is believed that acombination of a zinc salt which is effective at low pH in the stomach(such as zinc chloride and also zinc sulfate) and one or more of theorganic acid zinc salts as otherwise disclosed herein which areeffective at a higher pH, will maximize delivery of zinc to the stomachmucosa to obtain a favorable effect, at first by being dissolved in acidgastric juice in the stomach where an initial inhibition of acid occursand the pH rises, and subsequently, through absorption of zinc (from azinc salt) at a higher pH in the stomach or in the small intestine whereblood levels of zinc will increase to therapeutic levels. The absorptionand effect of a zinc salt at higher pH levels in the stomach or at thehigher pH of the small intestine (5.5-7.5 or higher) is advantageousbecause this delayed absorption of zinc will reduce gastric acidsecretion at a later time (than an initial effect at a low pH) over anextended period of time. Compositions according to the present inventionmay be administered a single time, but usually are administeredpreferably once or twice daily orally for a period ranging from about2-3 days to several months or longer.

Compositions according to the present invention also relate to sustainedor extended release formulations which comprise a first component whichallows or facilitates fast dissolution in the gastric juices at low pHso that a rapid inhibition of acid secretion is effected (withconcombinant increase in pH to a level of about 4.0 to about 5.0 orhigher) and a second component which releases zinc salt at the higher pHlevel in the stomach or more preferably, further in the small intestineon a sustained release basis in order to maintain an effective level ofzinc in the blood stream to inhibit gastric acid secretion in thestomach for extended periods. The first fast-acting component may bereadily formulated using a zinc salt which dissolves in gastric juice atlow pH (e.g., zinc chloride or zinc sulfate at a pH about 1.0 to about2.0) using standard excipients such as lactose, confectioner's sugar inpowered form, various stearate salts, etc, which dissolves rapidly inthe stomach and a second sustained or extended release formulation whichmakes us of any number of polymeric binders, matrices (polymeric and/orerodible), granules, or enteric coatings to allow release of zinc salton an extended or sustained release basis in the small intestine. Manyof these techniques are well known in the art. Exemplary patents such asU.S. Pat. No. 4,863,741 to Becker, U.S. Pat. No. 4,938,967 to Newton, etal., U.S. Pat. No. 4,940,556 to MacFarlane, et al., and U.S. Pat. No.5,202,128 to Morella, et al., among numerous others, may be useful forproviding teachings, all well known in the art, for formulating fastrelease/sustained or extended release formulations useful in the presentinvention.

The above formulations may be useful for providing enhancedbioavailabity of one or more zinc salts and optionally, other agentswhich may be useful in treating or reducing the likelihood of one ormore of gastric ulcers, GERD, NERD, Zollinger-Ellison syndrome, gastriccancer and reducing/inhibiting the secretion of acid in the stomach andraising the pH of the stomach to about 4.0 to about 5.0 or more, asotherwise disclosed in the present invention. It is noted that ininhibiting acid secretion in the stomach, blood concentrations of zincsalt of about 100 micromolar (μmol) produce inhibition of about 70%.With 300 μmol concentration of zinc salt, the inhibition approaches100%. The time of action of inhibition from the blood delivery side at100 μmol or 300 μmol is immediate (i.e., as soon as the zinc salt comesinto contact with the cell membrane, inhibition occurs. It may be shownthat inhibition occurs within about 10-15 minutes to 1 about hour in thepresence of secretagogue. The zinc salts may be administered orally(preferably no more than once or twice a day) or intravenously, alone orin combination with optional PPI drugs.

The use of zinc chloride alone, or in combination with at least oneadditional zinc salt as otherwise described herein is preferred.Additional preferred zinc salts include zinc acetate, zinc gluconate,zinc ascorbate, zinc succinate, and zinc amino acid chelates (mono- andbis-amino acid chelates). These zinc salts and combinations may be usedalone or in combination with additional agents such as a proton pumpinhibitor (esomeprazole, lansoprazole, omeprazole, pantoprazole orrabeprazole), an H2 blocker (cimetidine, famotidine, nizatidine orranitidine), an anti-H. pylori agent (amoxicillin, clarithromycin,metronidazole or tetracycline), a cytoprotective agent such as bismuthsubsalicylate or sucralfate, or a combination agent such as Helidac orPrevpac.

Pharmaceutical compositions comprising an effective amount of apharmaceutically acceptable zinc salt alone, or preferably incombination with at least one other zinc salt or an effective amount ofa traditional proton pump inhibitor such as such as esomeprazole,lansoprazole, omeprazole, pantoprazole or rabeprazole, an H2 blockersuch as cimetidine, famotidine, nizatidine or ranitidine, an anti-H.pylori agent, such amoxicillin, clarithromycin (biaxin), metronidazole(flagyl) or tetracycline, a cytoprotective agent such as bismuthsubsalicylate or sucralfate, or a combination agent such as Helidac orPrevpac, optionally in combination with a pharmaceutically acceptablecarrier, additive or excipient.

Pharmaceutical formulations include those suitable for oral, rectal,nasal, topical (including buccal and sub-lingual), vaginal or parenteral(including intramuscular, sub-cutaneous and intravenous) administration.Oral compositions or parenteral compositions (especially those for IVadministration) are preferred. Compositions according to the presentinvention may also be presented as a bolus, electuary or paste. Tabletsand capsules for oral administration may contain conventional excipientssuch as binding agents, fillers, lubricants, disintegrants, or wettingagents. The tablets may be coated according to methods well known in theart. Oral liquid preparations may be in the form of, for example,aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, ormay be presented as a dry product for constitution with water or othersuitable vehicle before use. Such liquid preparations may containconventional additives such as suspending agents, emulsifying agents,non-aqueous vehicles (which may include edible oils), or preservatives.When desired as discussed hereinabove, the present formulations may beadapted to provide sustained release characteristics of the activeingredient(s) in the composition using standard methods well-known inthe art. A composition which provides an effective amount of initialdose of zinc salt in the gastric juice at low pH followed by extendedrelease effects of zinc over a longer duration may be preferred.

In the case of combination pharmaceutical compositions, i.e., acomposition which comprises at least one water soluble salt incombination with a therapeutic agent (i.e., other than the zinc salt),compositions may be formulated in admixture or they may becompartmentalized in the dosage form. Pharmaceutical formulations may beformulated in admixture by mixing the actives together along with thepharmaceutically acceptable carriers, additives and/or excipients inpowder or liquid form and then using directly or presenting the mixturein tablet or capsule form. The compositions may be immediate release,sustained or controlled release or intermediate sustained or controlledrelease, depending upon the results desired. Formulations may also bepresented which compartmentalize the water soluble zinc salt and thetherapeutic agent into more than one portion of a tablet or capsule totake advantage of differential solubilities in order to enhance thebioavailability of the zinc salt and/or the additional therapeuticagents, using methods which are readily available in the art to those ofordinary skill.

In the pharmaceutical aspect according to the present invention, thecompound(s) according to the present invention is formulated preferablyin admixture with a pharmaceutically acceptable carrier. In general, itis preferable to administer the pharmaceutical composition orally, butcertain formulations may be preferably administered parenterally and inparticular, in intravenous or intramuscular dosage form, as well as viaother parenteral routes, such as transdermal, buccal, subcutaneous,suppository or other route, including via inhalation intranasally. Oraldosage forms are preferably administered in tablet or capsule(preferably, hard or soft gelatin) form. Intravenous and intramuscularformulations are preferably administered in sterile saline. Of course,one of ordinary skill in the art may modify the formulations within theteachings of the specification to provide numerous formulations for aparticular route of administration without rendering the compositions ofthe present invention unstable or compromising their therapeuticactivity.

In certain preferred embodiments, the present compositions arepreferably readily water soluble and mixtures of water-soluble zincs maybe used to effect an immediate release/sustained release pharmaceuticalprofile. This may maximize immediate effect and longer duration effectby simply choose the type of salt and adjusting the ratio of the zincsalt mixture accordingly. Of course, excipients can be chosen to affectthe delivery and bioequivalence of the zinc salts used. It is wellwithin the routineer's skill to modify the route of administration anddosage regimen of a particular compound in order to manage thepharmacokinetics of the present compounds for maximum beneficial effectto the patient.

Formulations containing the compounds of the invention may take the formof solid, semi-solid, lyophilized powder, or liquid dosage forms, suchas, for example, tablets, capsules, powders, sustained-releaseformulations, solutions, suspensions, emulsions, suppositories, creams,ointments, lotions, aerosols or the like, preferably in unit dosageforms suitable for simple administration of precise dosages.

The compositions typically include a conventional pharmaceutical carrieror excipient and may additionally include other medicinal agents,carriers, and the like. Preferably, the composition will be about 0.05%to about 75-80% by weight of a zinc salt compound or compounds accordingto the invention, with the remainder consisting of suitablepharmaceutical additives, carriers and/or excipients. For oraladministration, such excipients include pharmaceutical grades ofmannitol, lactose, starch, magnesium stearate, sodium saccharine,talcum, cellulose, glucose, gelatin, sucrose, magnesium carbonate, andthe like. If desired, the composition may also contain minor amounts ofnon-toxic auxiliary substances such as wetting agents, emulsifyingagents, or buffers.

Liquid compositions can be prepared by dissolving or dispersing thecompounds (about 0.5% to about 20%), and optional pharmaceuticaladditives, in a carrier, such as, for example, aqueous saline, aqueousdextrose, glycerol, or ethanol, to form a solution or suspension. Foruse in oral liquid preparation, the composition may be prepared as asolution, suspension, emulsion, or syrup, being supplied either inliquid form or a dried form suitable for hydration in water or normalsaline.

When the composition is employed in the form of solid preparations fororal administration, the preparations may be tablets, granules, powders,capsules or the like. In a tablet formulation, the composition istypically formulated with additives, e.g. an excipient such as asaccharide or cellulose preparation, a binder such as starch paste ormethyl cellulose, a filler, a disintegrator, and other additivestypically used in the manufacture of medical preparations.

The present invention also contemplates a route of administration otherthan an oral route. An injectable composition for parenteraladministration will typically contain the compound in a suitable i.v.solution, such as sterile physiological salt solution. The compositionmay also be formulated as a suspension in a lipid or phospholipid, in aliposomal suspension, or in an aqueous emulsion.

The pharmaceutical compositions of this invention may also beadministered by nasal aerosol or inhalation. Such compositions areprepared according to techniques well-known in the art of pharmaceuticalformulation and may be prepared as solutions in saline, employing benzylalcohol or other suitable preservatives, absorption promoters to enhancebioavailability, fluorocarbons, and/or other conventional solubilizingor dispersing agents.

Methods for preparing such dosage forms are known or will be apparent tothose skilled in the art; for example, see “Remington's PharmaceuticalSciences” (17th Ed., Mack Pub. Co., 1985). The person of ordinary skillwill take advantage of favorable pharmacokinetic parameters of thepro-drug forms of the present invention, where applicable, in deliveringthe present compounds to a patient suffering from a viral infection tomaximize the intended effect of the compound.

The pharmaceutical compositions according to the invention may alsocontain other active ingredients such as proton pump inhibitors, H₂blockers, antimicrobial agents, cytoprotective agents or combinationagents. In addition, compounds according to the present invention mayalso contain anti-cancer agents (to treat gastric cancer). Effectiveamounts or concentrations of each of the active compounds are to beincluded within the pharmaceutical compositions according to the presentinvention.

The individual components of such combinations may be administeredeither sequentially or simultaneously in separate or combinedpharmaceutical formulations.

When one or more of the compounds according to the present invention isused in combination with a second therapeutic agent active the dose ofeach compound may be either the same as or differ from that when thecompound is used alone. Appropriate doses will be readily appreciated bythose skilled in the art.

The following examples are used to describe the present invention. It isunderstood that they are merely exemplary and are understood not tolimit the breadth of the invention in any way.

EXAMPLES

The stomach produces acid to help break down food, making it easier todigest. In some cases, stomach acid can actually irritate the lining ofthe stomach and the duodenum (top end of the small intestine). Sometimesthe acid “refluxes” upwards and irritates the lining of the esophagus.Irritation of the lining of the stomach or the esophagus causes acidindigestion (heartburn) and sometimes causes ulcers or bleeding.

We show in this particular application that ZnCl₂ has a potentinhibitory effect on gastric acid secretion at the cellular level byabolishing the activity of the gastric H⁺,K⁺-ATPase in rat and humangastric glands. We also demonstrate that addition of micromoleconcentrations of ZnCl₂ can effectively prevent histamine dependent acidsecretion in whole rat stomachs and through a ZnCl₂ enriched diet.

Material and Methods

Animals. Sprague-Dawley rats 150-250 g (Charles River Laboratory)) werehoused in climate- and humidity-controlled, light-cycled rooms, fedstandard chow with free access to water, and handled according to thehumane practices of animal care established by the Yale Animal Care.Prior to experiments, animals were fasted for 18-24 hours with freeaccess to water.

Isolation of rat and human gastric Glands. Following removal of thestomach, the stomach was opened longitudinally and the corpus and antrumisolated and sliced into 0.5 cm square sections, and washed with coldRinger solution to remove residual food particles. The tissues weretransferred to the stage of a dissecting microscope. Individual glandswere isolated using a hand-dissection technique as describedpreviously³⁶. Following isolation, individual isolated glands wereallowed to adhere to cover slips that had been pre-coated with Cell-Tak(Collaborative Research, Bedford, Mass.) and were transferred to thestage of an inverted microscope.

The human tissue was transferred from the OR in a HEPES-buffered Ringersolution. The tissue was stored on ice and immediately the isolatedglands were dissected as described above.

Digital imaging for intracellular pH. Isolated gastric glands wereincubated in a HEPES-buffered Ringer's solution containing either 10μmol of the pH-sensitive dye BCECF-AM(2′,7′)-bis-(2-carboxyethyl)-5-(and-6)-carboxy-fluorescin, aceto-methylester (Molecular Probes, Eugene, Oreg.) for 10 minutes as describedpreviously³⁷⁻³⁹. Following dye-loading the chamber was flushed with aHEPES solution to remove all non-de-esterified dye. The perfusionchamber was mounted on the stage of an inverted microscope (OlympusIX50), which was used in the epifluorescence mode with a 40× objective.BCECF was successively excited at 440 nm and 490 nm from a monochromatorlight source, and the resultant fluorescent signal was monitored at 535nm using an intensified charge-coupled device camera. Individual regionsof interest were outlined and simultaneously monitored every 15 sec.during the course of the experiment. A minimum of 8 cells or regions wasselected per gland.

Proton extrusion by individual parietal cells was monitored by observingrecovery of pH_(i) after acid loading the cells with Na⁺ free HEPESsolution containing 20 mM NH₄C1. Parietal cells were subsequentlysuperfused with Na⁺ free HEPES, which abolished all Na⁺/H⁺ Exchanger(NHE) activity, trapping H⁺ within the cytosol and initiating animmediate drop in pHi. Under these conditions, the only potential H⁺extrusion pathway is via the H⁺,K⁺-ATPase activation.

The intensity ratio data (490/440) were converted to pH values using thehigh K⁺/nigericin calibration technique⁴⁰. Intracellular pH recoveryrates were calculated from the same initial starting pH to eliminate thepotential variation in the individual intracellular buffering power ofthe cells under the different experimental conditions. All dataincluding the individual images for all wavelengths were recorded to thehard disk which allowed us to return to the individual images after theexperiment for further analysis. The recovery rates are expressed as theΔpH/min, and were calculated over the pH range of 6.5-6.8. All chemicalswere obtained from Sigma and Molecular Probes. All data were summarizedas means±SE and were analysed by grouping measurements at baselinevalues.

Whole stomach pH measurements. Before the experiments animals werefasted for 24 h to reduce basal acid secretion to a consistent minimum.Animals were killed with an overdose of isoflurane and an abdominalincision was made. The stomach was ligated at the duodenal andesophageal junction and excised. Then 1 ml of non buffered, isotonicsaline (140 mM) was infused into the lumen of the stomach. This volumedid not distend the stomach, thus avoiding potential stimulation of acidsecretion by stretch. The stomachs were then placed in either oxygenatedHEPES-buffered Ringer solution or in the same solution containing 100 μMhistamine alone or additionally 300 μM ZnCl₂ (pH 7.4) and maintained at37° C. After 1 hour the stomach contents were aspirated and the pH wasrecorded.

Oral Zinc supplementation in rats. These studies were designed tomodulate acid secretion by increasing dietary zinc. In these studies weused an oral ZnCl₂ solution (zinc chloride in tap water). The animalshad free access to food and the zinc containing water for the durationof the study. 150 mg/kg/d or 0.5 mg/kg/d ZnCl₂ was added to the drinkingwater for 5 days. Animals had free access to water prior to theexperiment and were fed with standard chow until 24 hours before theexperiment, at which point they had free access to ZnCl₂ containingwater only. After the 5 days exposure period and the 24 hour fast, theanimals were sacrificed and a total gastrectomy was performed on theanimals. Individual gastric glands were isolated with the handdissection technique described above.

Results

Histamine induced acid secretion in human and rat is inhibited by ZnCl₂.In the first series pH_(i) measurements of single parietal cells withinfreshly isolated gastric glands were used to measure H⁺,K⁺-ATPaseactivity. The activity of the proton pump was calculated from the rateof alkalinization of pH_(i) (ΔpH_(i)/min) after acidification using theNH4Cl prepulse technique in the absence of sodium and bicarbonate. H⁺extrusion under these conditions depends on the activity of theH⁺,K⁺-ATPase, as previously shown⁴¹. In the absence of any stimulation,only a low rate of pHi recovery was observed (0.011±0.002 units/min,n=32 cells from 3 glands from 3 animals; FIG. 1 E). After exposure ofthe rat gastric glands to histamine (100 μM), the alkalinization rateincreased to 0.051±0.004 pH units/min (n=60 cells from 15 glands from 8animals; FIG. 1 A). Adding 300 μM ZnCl₂ to the superfusion bath in thepresence of histamine (100 μM) prevented the stimulatory effect ofhistamine on the Na⁺-independent recovery rate (0.0012±0.004 pHunits/min) and reduced it to the same level as seen in the controlglands not exposed to histamine (n=60 cells from 6 glands from 4animals); FIG. 1 B). Human gastric glands showed also a robust protonefflux under histamine stimulation. This effect was abolished by ZnCl₂(FIG. 1C, D); (n=26 cells, 3 glands). Thus the freshly isolated rat andhuman gastric glands showed H⁺,K⁺-ATPase activity that could bestimulated by histamine and inhibited by ZnCl₂.

ZnCl₂ inhibits rat acid secretion in a dose dependent manner. ZnCl₂inhibited H⁺ extrusion in a dose dependent manner (FIG. 2). In thisprotocol acid secretion was stimulated by histamine and expressed asΔpH_(i)/min. Therefore rat gastric glands were incubated with 100 μMhistamine (15 min) and histamine was present throughout the entireexperiment. To investigate the inhibitory potency of ZnCl₂ we useddifferent concentrations (25 μM-300 μM). ZnCl₂ was present during theentire experiment, including the histamine incubation period of 15 min.300 μM ZnCl₂ showed a 98% inhibition of proton extrusion compared to theHistamine induced rate and the control.

Fast onset and reversible inhibition of gastric acid secretion by ZnCl₂.There are irreversible (i.g. omeprazole) and reversible (P-CAB's) acidblockers available⁴². We investigate the reversibility of the inhibitoryeffect of ZnCl₂ in our in vitro setting. Thus we stimulated acidsecretion with histamine (100 μM) during the entire experiment. When theintracellular alkalinization (acid secretion) was observed, ZnCl₂ (300μM) was added to the superfusion bath. The acid secretion was abolishedafter a few seconds (FIG. 3 A). After the removal of ZnCl₂ in the sameexperiment acid secretion returns to normal levels. We were also able todemonstrate reversibility following incubation and superfusion ofparietal cells over 20 min with ZnCl₂ (300 μM) and histamine (100 μM).After removal of ZnCl₂ from the superfusion bath the intracellularalkalinization (proton extrusion) proceeded at normal uninhibited rate(FIG. 3 B).

Oral Zinc supplementation reduces basal rat gastric acid secretion.These studies were designed to modulate acid secretion by increasingdietary zinc. 150 mg/kg/d or 0.5 mg/kg/d ZnCl₂ were added to thedrinking water for 5 days. The H⁺ extrusion rate was measured with BCECFas described before. Histamine stimulated parietal cells showed a robustrecovery rate (proton extrusion) of 0.051±0.004 (n=120 cells from 15glands from 8 animals). FIG. 4 shows that the ZnCl₂ (150 mg/kg/d or 0.5mg/kg/d) in the drinking water decreased the histamine induced acidsecretion significantly in comparison to the control group withhistamine alone. 150 mg/kg/d: 0.022±0.0045; (n=60 cells from 10 glandsfrom 3 animals), 0.05 mg/kg/d: 0.034±0.0036; (n=60 cells from 6 glandsfrom 4 animals).

ZnCl₂ decreased gastric acid production ex vivo. To determine whetherZnCl₂ could inhibit gastric acid secretion in the whole organ, weexamined luminal pH in freshly isolated rat stomachs after incubation inHEPES or in the same solution the presence of 100 μM histamine or both,100 μM histamine and 300 μM ZnCl₂. As illustrated in FIG. 5, in thepresence of histamine mean luminal pH was lower than in control stomachpreparations incubated in HEPES alone (3.15±0.27 vs. 4.59±0.48, n=9 foreach, P<0.005). In the presence of histamine and ZnCl₂ the luminal pHwas nearly as high as in the control group without stimulation althoughthis findings were not significant (4.54±0.065 vs. 4.59±0.48, n=8 eachgroup, P>0.005).

Different Zinc Salts shows different efficacy in raising intraluminalpH. Measurements of whole stomach intraluminal pH using a number of zincsalts according to the present invention were made to assess effect ofsalt and concentration on intraluminal pH. Isolated whole stomachpreparations from rats were cannulated at the esophageal and duodenaljunction and perfused in vitro with 37° C. pH 7.4 Ringers solution. Theblood perfusate was then exposed to 100 μM Histamine to induce acidsecretion. The lumen of the stomach was infused with 0.5 cc ofnon-buffered isotonic saline. In some studies one of the following zincsalts was added to the lumen perfusate at a final concentration of 300μM (zinc chloride, zinc sulfate, zinc acetate, zinc citrate). The dataare the sum of 5 separate stomachs from 5 separate animals for each ofthe columns. Data are the mean of all studies with the standard error ofthe mean displayed. Those results appear in attached FIG. 6.

Discussion

In this study, we examined the dose dependent inhibition of gastric acidsecretion by ZnCl₂ in human and rat gastric glands. Furthermore we triedto evaluate the onset of effect of ZnCl₂ and used whole stomachpreparation as well as oral Zinc supplementation to investigate theeffect on gastric acid secretion.

Acid secretion was induced by the classically known secretagoguehistamine, which led to a robust proton extrusion via the H⁺,K⁺-ATPasein comparison to basal acid secretion in the resting, unstimulated gland(FIG. 1 e). In subsequent studies we examined the inhibitory effects ofZnCl₂ on secretagogue sensitive gastric acid secretion. We confirmed theinhibitory potency of ZnCl₂ (300 μM) on histamine induced acidsecretion. ZnCl₂ inhibits acid secretion in the single gastric gland ina dose dependent manner. ZnCl₂ abolished proton extrusion to a levelcomparable to that of the control experiments in both, human and ratgastric glands (FIG. 1). This dose would be equivalent to 40 mgsupplementation per day in humans. The daily recommended amount of Zincintake is 11 mg. In the literature the amount considered to be toxic is10 times higher. Therefore 40 mg of ZnCl₂ as an oral acid blocker wouldbe significantly lower than reported toxic doses. In addition a similaramount of ZnCl₂ also prevented acid secretion in ex vivo whole stomachpreparations (FIG. 5). In these experiments ZnCl₂ was applied to theluminal side of the stomach and it can thus be concluded that the metalion is working directly on the H⁺,K⁺-ATPase of the parietal cell orenters the cell to modulate the signalling pathway of acid secretion. Itremains unclear how ZnCl₂ enters the cell. Previous studies describedZinc entry into the cell through voltage dependent Ca²⁺-channels and/orthe HCO₃/Cl⁻ exchanger on the basolateral membrane. Orally applied ZnCl₂confirmed our previous results. Proton extrusion by ZnCl₂ treated ratswas significant lower than acid secretion by our control group (FIG. 4).The control refers to histamine stimulated. In the figure, zinc treatedglands are still higher than the control (non-histamine treated) alone.

As mentioned in the introduction proton pump inhibitors have a delayedonset of acute action and the full inhibitory effect is slow requiringseveral dose cycles. For example omeprazole reaches only 30% inhibitionof acid secretion on the first day of treatment⁴³. Our studycharacterizes the rapid onset of action ZnCl₂ as well as itsreversibility. Faster onset of effect and increased duration of actionwould offer improvement for patients with GERD and other acid relateddisorders. In fact as shown in FIG. 5 a we were able to inhibithistamine induced acid secretion during maximal proton extrusion byaddition of 300 μM ZnCl₂. On the other hand histamine induced acidsecretion continued after removal of ZnCl₂ from the superfusion bathdemonstrating the reversible nature of ZnCl₂ (FIG. 3 b). In summary ourfindings indicate that ZnCl₂ offer a more rapid and prolonged inhibitionof gastric acid secretion. It is a reversible and fast acting inhibitorof acid secretion in single rat and human gastric glands and also inwhole stomach preparations.

Such treatment may provide significant benefit to patients with GERD.Future studies investigating the exact mechanism by which ZnCl₂ inhibitsacid secretion are necessary and will help define its future place inthe treatment of acid related diseases in the clinical setting.

Fundic Region

In the following examples, it is shown that the fundic region of thestomach and the fundic glands contain functional acid secretoryproteins. Furthermore, it is shown that the fundic glands have a sodiumand potassium independent protein the proton ATPase commonly referred toas the Vacuolar H⁺-ATPase. The evidence consists of immunofluorescencedata using a antibody directed against the a Subunit of the H⁺-ATPaseand functional data (FIGS. 7-10) in which the extrusion rate of protonsfrom these cells in the absence of Na and K is measured. Further thereis evidence that this process is amplified in the presence of histaminea compound that was thought to only influence the gastric H⁺,K⁺-ATPasefound in the parietal cells in the body of the stomach. This activity isdemonstrated in both the rat model and in humans in gastric resectionstaken from patients undergoing gastric reduction surgery.

Materials and Methods Animals and Chemicals

Male Sprague Dawley rats weighing 200-300 g were housed in climate andhumidity controlled, light cycled rooms and fed standard chow with freeaccess to water. Prior to experiments, animals were fasted whileallowing free access to water for 18-24 hours to reduce basal acidsecretion. Following isoflurane anesthesia the animals were sacrificed,an abdominal incision was made exposing the stomach. After isolating theesophagus and duodenal junctures a total gastrectomy was performed with1-2 cm of esophagus remaining attached to the gastrectomy. We includedthe esophageal juncture to have a common landmark for all fundicisolations. While holding the esophagus with forceps approximately 3 mmof fundus was removed with 5 mm of the intact esophagus.

Fundic Gland Isolation

The removed fundic tissue was placed in ice cold HEPES-bufferedRinger-solution (pH adjusted to 7.4 at 4° C.) and transferred to thestage of a dissection microscope. The fundic glands were visualizedunder the microscope at 50× magnification. Glands adjacent to theesophageal junction were hand dissected. Following isolation, individualglands were adhered to cover slips that had been pretreated with thebiological adhesive Cell-Tak (Cell-Tak™ cell adhesive, BD Biosciences;Bedford, Mass.)

Immunohistochemistry/Immunofluorescence

Male Wistar rats (200-250 g) were anesthetized with pentobarbital i.p.and perfused through the left ventricle with PBS followed byparaformaldehyde-lysine-periodate (PLP) fixative as previouslydescribed^(19a). Stomachs were removed, cleaned from food residues, andfixed overnight at 4° C. by immersion in PLP. Stomachs were washed threetimes with PBS and sections were cut at a thickness of 5 μm aftercryoprotection with 2.3 M in PBS for at least 12 h. Immunostaining wascarried out as described previously^(20a). Sections were incubated with1% SDS for 5 min., washed 3 times with PBS and incubated with PBScontaining 1% bovine serum albumin for 15 min prior to the primaryantibody. The primary antibodies (mouse monoclonal anti human β gastricH⁺,K⁺-ATPase (Affinity Bioreagents, CA, USA) diluted 1:50 in PBS andapplied overnight at 4° C. Sections were then washed twice for 5 minwith high NaCl PBS (PBS+2.7% NaCl), once with PBS, and incubated withthe secondary antibody (donkey anti-rabbit Alexa 546, Molecular Probes,Oregon) at a dilution of 1:1000 for 1 h at room temperature. Sectionswere washed twice with high NaCl PBS and once with PBS before mountingwith VectaMount (Vector Laboratories, Burlingame, Calif.). The specimenswere viewed with a Nikon E-800 microscope.

ImmunoGold Labeling

Rats were anaesthetized using 5 ml of a 10% sodium pentobarbital giveni.p. Fixation was done through a left ventricle cardiac perfusion usingPBS and then PLP. The stomach was removed and fixed in PLP for 4 hoursand then transferred to holding buffer overnight. Frozen and Eponsections of the gastro esophageal junction were made and slices weretaken for gold labeling and electron microscopy.

Hematoxylin and Eosin Staining

Rats were anaesthetized using 5 ml of a 10% sodium pentobarbital giveni.p. Fixation was done through a left ventricle cardiac perfusion usingPBS to flush the animal and then Karnovsky Fixative for 2 hours and thenin holding buffer overnight. A section of the gastro esophageal junctionwere made and slices taken for Electron Microscopy morphology of theH⁺,K⁺-ATPase protein and Hematoxylin/Eosin staining of the glands at thegastro esophageal junction.

Measurements of Intracellular pH (pH_(i)) Measurements of IsolatedFundic Glands

Using the same protocol that we developed for isolated corpus glandperfusion^(20a, 21a) individual fundic glands were loaded with a 1004concentration of the pH sensitive dye (BCECF,(2′7-bis(2-carbocyethal)-5-(and 6)-carboxyflurorescein-acetomethylester;Molecular Probes, OR USA)) for 15 minutes. Following the loading period,the perfusion chamber was mounted on the stage of an inverted microscope(Olympus IX50) attached to a digital imaging system (Universal ImagingCorp; Dowingtown, Pa.), and perfused with HEPES buffered Ringer-solutionfor 5 min at 37C.° to remove any unesterified dye. Measurements wereperformed in the epifluorescence mode with 60×/0.80 and 40×/0.90objectives. BCECF was successively excited at 440±10 nm and 490±10 nm,the resultant intracellular fluorescent signal was monitored at 535 nmusing an intensified charge-coupled device camera. Data points wereacquired every 15 s. The resulting 490/440 intensity ratio data wereconverted to intracellular pH (pH_(i)) values using the highK⁺/Nigericin calibration technique^(22as, 22as). Acid extrusion wasmonitored in the absence of bicarbonate. The rate of intracellularalkalinization was measured after using the NH₄Cl-prepulsetechnique^(22a, 23a), which resulted in a reproducible and sustainedintracellular acidification. Intracellular pH recovery rates (H⁺,K⁺-ATPase activity) were measured in Na⁺ free HEPES solutionscontaining: 1) 100 μM histamine 2) 100 μM pentagastrin. 3) 100 μMacetylcholine 4) 100 μM histamine+omeprazole at 100 μM and 200 μMconcentrations.

Intracellular pH recovery rates were calculated from the same initialstarting pH to eliminate the potential variation in the individualintracellular buffering power of the cells under the differentexperimental conditions. All data including the individual images forall wavelengths were recorded to the hard disk which allowed us toreturn to the individual images after the experiment for furtheranalysis. The recovery rates are expressed as the ΔpH_(i)/min, and werecalculated over the pH range of 6.5-6.9.

Activation of acid secretion via histamine, acetylcholine orpentagastrin was induced by preincubation of the glands for 15 minbefore the experiment combined with BCECF (100 μM) loading. All data aresummarized as mean±S.E. Significance was determined using the one-wayANOVA test with p<0.05 considered to be statistically significant. Allchemicals used were obtained from Sigma and Molecular Probes.

Results Immunohistochemical Localization of the H⁺, K⁺-ATPase

Immunohistochemistry using specific antibodies directed against highlyconserved epitopes within either the α or β subunits of the gastric H⁺,K⁺-ATPase identified specific staining for both subunits in the fundicglands (FIG. 7 A).

Electron Microscopy

After obtaining Epon sections of fasted rat gastro esophageal junctionElectron Microscopy was done on the gastric glands that came right afterthis junction and those we named F1 and used in all of our experiments.FIG. 7 B, C shows the gold tag localization to the H⁺, K⁺-ATPase in theparietal cell from the Fundic gland. We noticed a higher density ofstaining on the apical pole of the cell in the secretory or vacuolarcanaliculi. This may correlate with the fundic regions high basal protonextrusion rates in comparison to the corpus due to the fact that theprotein is always at the membrane in the fundic gland whereas in thecorpus the receptor is inside the secretory canaliculus untilstimulation.

H2 Receptor Staining

H2 receptor staining was done on both the fundus and corpus to examinethe presence and density of the receptor in both the areas of thestomach. We found clear basolateral staining in the corpus glands andcould not detect staining in the fundic glands. These results correlatewith the lack of effect by histamine in stimulating fundic acidsecretion. It was clearly seen that the H2 receptor is absent in theglands of the fundus and present in the corpus (data not shown)

Secretagogue Induced Acid Secretion

Intracellular pH was measured using the pH sensitive dye BCECF andmonitored continuously using a real time fluorescence imaging system toidentify changes in intracellular pH. Rates of proton efflux werecalculated as ΔpH_(i)/min using a technique that was developed in ourlaboratory for corpus glands^(21a-25a). We measured the change in rateof efflux in the presence and absence of secretagogues.

Histamine Effect on Fundic and Corpus H⁺, K⁺-ATPase

We incubated individual glands with 100 μM histamine for 20 minutes.Histamine was present during the whole superfusion protocol. In thecorpus gland we measured a histamine stimulated proton extrusion rate of0.056±0.008 ΔpH_(i)/min whereas the basal acid secretion without anysecretagogues was 0.011±0.002 ΔpH_(i)/min (FIG. 8C, D). In comparison tothe corpus the fundus showed even under basal conditions a high protonextrusion rate (0.039±0.009 ΔpH_(i)/min). This is similar to thehistamine induced acid secretion (0.040±0.0079 ΔpH_(i)/min, FIG. 8 A, B)This data shows that there is no effect of histamine on F1 zone glandsin comparison to controls.

Acetylcholine and Fundic Acid Secretion

In the next series we investigated the functional properties of fundicglands according to the neuronal stimulation via ACH. In contrast tohistamine there was a noticeable change in proton extrusion rates afterstimulation. Although the controls were still actively pumping outprotons the glands that were stimulated with 100 μM of acetylcholine for20 minutes during the dye loading and throughout the perfusion. Wedetermined that acetylcholine caused an increase in the rate ofalkalinization (0.075±0.0015 ΔpH_(i)/min vs. controls 0.039±0.009ΔpH_(i)/min) showing a direct effect of acetylcholine on fundic acidextrusion (FIG. 9).

Pentagastrin Effect on the F1 Zone

To determine if gastrin could also activate the fundic H⁺, K⁺-ATPase weconducted studies using pentagastrin, a synthetic peptide containing theentire five terminal amino acids of gastrin, which is know to causerobust acid secretion in corpus glands. At a dose of 100 μM pentagastrinwe observed alkalinization rates that were 0.062±0.007 ΔpH_(i)/min whichwas similar to acetylcholine in terms of enhancing the rate of protonextrusion from fundic cells (FIG. 9).

Inhibitors of Gastric Acid Secretion

In the next series of studies we tried to determine if the fundic glandshad similar H⁺, K⁺-ATPase inhibitor profiles as observed in the corpus.We chose the well characterized inhibitor of the gastric H⁺, K⁺-ATPaseomeprazole and the P-CAB (potassium competitive acid blocker)AZD0865.^(26,27).

Omeprazole Effect on the F1 Zone and Corpus

As shown in FIG. 10 A, omeprazole did not inhibit acid secretion usingthe same concentration that completely inhibited secretagogue inducedacid secretion in the corpus (FIG. 10 B). At even a higher dose thanwhat normally inhibits acid secretion in the corpus the fundus continuedto extrude protons. The fundic glands were preincubated with 200 μMomeprazole and 100 μM histamine and then perfused with omeprazole andhistamine throughout the entire experiment. Alkalinization rates were0.045±0.002 ΔpH_(i)/min compared to only histamine stimulated controlsat a rate of 0.042±0.007 ΔpH_(i)/min. In contrast acid secretion in thecorpus glands was abolished by 200 μmol omeprazole (0.014±0.002ΔpHi/min.), (FIG. 10 B).

AZD0865 Effect on the F1 Zone in Comparison to the Corpus:

Also shown in FIG. 10 (C, D), P-CAB AZD0865 effectively inhibits acidsecretion in the corpus at a 10 μM concentration; however at that sameconcentration the F1 zone still has potassium dependant recovery. In thefundus the intracellular pH increased at a rate of 0.031±0.006ΔpH_(i)/min. In the Corpus at the same concentration of 10 μM therecovery rate was 0.021±0.008 ΔpH_(i)/min.

Table 1

Composition of solutions used for intracellular pH measurements insingle rat gastric glands. All concentrations are given in Mm. NMDG isN-Methyl-D-Glucosamine, all solutions were titrated to pH 7.4 at 37° C.using either NaOH or KOH. NMDG was titrated with HCL.

TABLE 1 Solution 1: Solution 2: Solution 3: Solution 4: Standard Na⁺ -free Na⁺ - free High K⁺ HEPES HEPES HEPES + NH4Cl calibration NaCl 125 —— — NMDG — 125 125 125 NH₄Cl — — 20 — KCl 3 3 3 105 MgSO₄ 1.2 1.2 1.21.2 CaCl₂ 1 1 1 1 Glucose 5 5 5 — HEPES 32.2 32.2 32.2 32.2 pH 7.4 7.47.4 7.0

Discussion

In this study we have provided evidence that the fundic region of thestomach contains glands that are capable of secreting acid via thegastric H⁺, K⁺-ATPase. In our study we have for the first timecharacterized the acid secretory properties of the fundus. We providemorphological, immunohistochemical and functional evidence for H⁺,K⁺-ATPase protein activity in the fundus In our morphological studies wefirst had to delineate where the fundus began and ended. As it isunderstood that this region begins at the gastro esophageal junction wedecided to take glands from this junction point until the initiation ofthe greater curve of the fundus. We took tissue sections from what wecalled the F1 zone starting from the gastro esophageal junction andcontinued 2 mm distally. We found these glands to be quite different inshape and also in parietal cell like density. To confirm that parietalcells in F1 contain H⁺, K⁺-ATPase we stained for the α and β subunit(FIG. 7 shows the staining for the α subunit).

During our investigation of secretagogue induced fundic acid secretionwe were able to demonstrate that histamine is not the most potentstimulator of acid secretion in the fundus as it is in the corpus. Infact, very little difference was seen in glands that were not stimulatedcompared to those stimulated with histamine (FIGS. 8 and 9). This resultwas confirmed by a lack of staining for the H2 receptor in the fundus(data not shown). Acetylcholine was the most robust of the threesecretagogues in the fundus, which may relate to the close proximity ofthe vagal nerve to the fundic region. As this section of the stomachstretches when food is present, there is vagal stimulation^(28a-30a)with associated acetylcholine secretion. This finding is especiallyimportant when considering clinical problems in obese patients who havegastro esophageal reflux disease (GERD). This can be correlated to thebenefits patients with sever ulcer disease gain when undergoing avagotomy after not gaining relief from medical management^(31a-33a).

Another interesting finding is the lack of inhibition by omeprazole onfundic acid secretion although they are immunoreactive with antibodiesfor the gastric H⁺, K⁺-ATPase. We were unable to inhibit basal orsecretagogue (histamine) induced fundic acid secretion with the protonpump inhibitor omeprazole (FIG. 10 A) at doses that were double thatwhich effectively eliminated all acid secretion in the corpus (FIG. 10B). These findings are in direct contrast to our data (FIG. 8 C,D)^(20a, 21) a, 24 a, 25 a and others findings in glands from thecorpus^(34a-38a) This finding has an interesting clinical correlate inthat there is an increasing number of patients suffering from GERD thatare not effectively treated with PPI's. ^(39a)One possible explanationfor the lack of omeprazole sensitivity could be that as omeprazole needsto be acid activated, a lack of a canaliculi like space would preventthe concentration of acid and potentially prevent the acid activation ofthe drug. As shown in FIG. 7 B, C using immunogold tag labeling we seethat there is indeed a secretory space and that the pumps appear to linethe apical surface of this space. With previous theories of acidsecretion came the many dictums for surgical and medical modalities oftreatment which focused on the corpus. Of interest is the recentincidence of GERD like symptoms in gastric bypass patients who followingthe procedure are left only with a small part of the fundus, and littleto no functional corpus. In those symptomatic patients there has beenlittle to no success using classical PPI's^(40a) which now can bepossibly be explained by our recent findings. Our findings demonstratethat the fundic region of the stomach is much more than a holding areaand in fact can secrete acid in response to secretagogue stimulation,furthermore the H⁺, K⁺-ATPase found in this segment appears insensitiveto omeprazole. These results can lead to important new targets forpatients that are PPI resistant or have recurrent reflux symptoms in thepresence of PPI therapy.

Results:

Fundic glands showed a distinct morphology compared to corpus glands(elongated and lacking typical bulging parietal cells).Immunofluorescence (α and β subunit of the H⁺, K⁺-ATPase) and immunogoldlabeling (β subunit) were both positive in the fundic region. Fundicgland proton extrusion rates were stimulated by gastrin andacetylcholine but were not influenced by histamine. Finally acidsecretion of stimulated fundic glands could not be inhibited by the H⁺,K⁺-ATPase inhibitor omeprazole.

CONCLUSION

The fundic region of the stomach secreted acid via the H⁺,K⁺ATPase, andwas not sensitive to proton pump inhibitors. Our findings demonstratethat the fundic region of the stomach is much more than a holding areaand in fact can secrete acid in response to secretagogue stimulation,except histamine.

The digestion of food by the stomach requires a complex combination ofhormonal and neuronal events. Generally it has been thought that thecorpus or body of the stomach secretes acid via the parietal cells andthe antrum secretes bicarbonate to neutralize the digestate by raisingthe pH of the stomach contents ^(1a-9a). During this process theperistaltic movements of the stomach result in contractions that pushthe food upward into the fundic section of the stomach where it transitsbefore exiting into the small intestine^(10a). In this model ofdigestion the fundus acts only as a holding zone and is not involved inacid secretion^(4a-11a). Classical gastric acid secretion in the corpusoccurs when the H⁺, K⁺-ATPase gets stimulated by secretagogues andbegins to secrete protons into the secretory canaliculus after beingtrafficked to the apical membrane from their cytoplasmictubulovesicles^(12a). The parietal cell has at least three activatingreceptors on its basolateral membrane, i.e. histamine H2, acetylcholineM3 and Gastrin CCK-B. It is well accepted that the H2 receptor couplesto Gs to activated adenylate cyclase producing cAMP and subsequentactivation of cAMP dependant protein kinase. The acetylcholine andgastrin receptor couple through a non Gs system probably Gq to activatephospholipase C producing IP3 and diacylglycerol. Acetylcholine releasesintracellular Ca²⁺ and gastrin activating protein kinase C^(13a). Afterthis cascade of intracellular events the parietal cell extrudes protonsvia the H⁺, K⁺-ATPase pump which exchanges intracellular H⁺ ions forextracellular K⁺ ions in an electroneutral ratio^(14a).

Recent observations in patients who have undergone gastric bypasssurgery present an interesting paradigm, namely that only left with asmall fundic region postoperatively, they still have acid secretionwhich in some patients leads to reflux symptoms, ulcers and entericcontent leaks^(15a). Of note is that many of these patients have littlesuccess in abating the symptoms while on proton pump inhibitor (PPI)therapy^(16a-18a). From these initial clinical observations we raisedthe question: does the fundus play a role in the production of acid, andhow similar are its properties to corpus secretory proteins. We alsowere interested in determining fundic sensitivity to classicalsecretagogues and therefore conducted studies using histamine,pentagastrin, and acetylcholine.

In the present experiment we have investigated the acid secretoryproperties of the rat fundus under resting and secretagogue stimulatedstates, furthermore we elucidate fundic response to an inhibitory drugof acid secretion. Our data demonstrate that the fundic region is anactive secretory zone in the stomach and contains a gastric H⁺,K⁺-ATPase that can be stimulated by secretagogues but appears to beinsensitive to omeprazole. Zinc therapy according to the presentinvention is a means to regulate acid release in the fundus region.

REFERENCES First Set

-   1. Hersey S J, Sachs G. Gastric acid secretion. Physiol Rev 1995;    75:155-189.-   2. Sachs G, Prinz C, Loo D, Bamberg K, Besancon M, Shin J M. Gastric    acid secretion: activation and inhibition. Yale J Biol Med 1994;    67:81-95.-   3. Sachs G. Physiology of the parietal cell and therapeutic    implications. Pharmacotherapy 2003; 23:68 S-73S.-   4. Horie S, Yano S, Watanabe K. Effects of drugs acting on Cl(−)-.    Eur J Pharmacol 1992; 229:15-19.-   5. Helander H F, Keeling D J. Cell biology of gastric acid    secretion. Baillieres Clin Gastroenterol 1993;7:1-21.-   6. Soumarmon A, Lewin M J. Gastric (H+,K+)-ATPase. Biochimie 1986;    68:1287-1291.-   7. Wolfe M M, Welage L S, Sachs G. Proton pump inhibitors and    gastric acid secretion. Am J Gastroenterol 2001; 96:3467-3468.-   8. Aihara T, Nakamura E, Amagase K, Tomita K, Fujishita T, Furutani    K, Okabe S. Pharmacological control of gastric acid secretion for    the treatment of acid-related peptic disease: past, present, and    future. Pharmacol Ther 2003; 98:109-127.-   9. Gardner J D, Sloan S, Miner P B, Robinson M. Meal-stimulated    gastric acid secretion and integrated gastric acidity in    gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;    17:945-953.-   10. Williams J L. Gastroesophageal reflux disease: clinical    manifestations. Gastroenterol Nurs 2003; 26:195-200.-   11. Lehmann F, Hildebrand P, Beglinger C. New molecular targets for    treatment of peptic ulcer disease. Drugs 2003; 63:1785-1797.-   12. Brzozowski T, Konturek P C, Konturek S J, Drozdowicz D, Kwiecien    S, Pajdo R, Bielanski W, Hahn E G. Role of gastric acid secretion in    progression of acute gastric erosions induced by    ischemia-reperfusion into gastric ulcers. Eur J Pharmacol 2000;    398:147-158.-   13. Franzin G, Manfrini C, Musola R, Rodella S, Fratton A. Chronic    erosions of the stomach—a clinical, endoscopic and histological    evaluation. Endoscopy 1984; 16:1-5.-   14. Raugstad T S, Svanes K, Ulven A, Moister A. Interaction between    acute gastric ulcer and epinephrine-induced mucosal erosions in the    rat: the significance of gastric acid secretion. Digestion 1979;    19:70-72.-   15. Houghton J, Stoicov C, Nomura S, Rogers A B, Carlson J, Li H,    Cai X, Fox J G, Goldenring J R, Wang T C. Gastric cancer originating    from bone marrow-derived cells. Science 2004; 306:1568-1571.-   16. Bell N J, Hunt R H. Progress with proton pump inhibition. Yale J    Biol Med 1992; 65:649-657.-   17. Garnett W R. Lansoprazole: a proton pump inhibitor. Ann    Pharmacother 1996; 30:1425-1436.-   18. Robinson M. Drugs, bugs, and esophageal pH profiles. Yale J Biol    Med 1999; 72:169-172.-   19. Tutuian R, Katz P O, Castell D O. Nocturnal acid breakthrough:    pH, drugs and bugs. Eur J Gastroenterol Hepatol 2004; 16:441-443.-   20. Adachi K, Komazawa Y, Fujishiro H, Mihara T, Ono M, Yuki M,    Kawamura A, Karim Rumi M A, Amano Y, Kinoshita Y. Nocturnal gastric    acid breakthrough during the administration of rabeprazole and    ranitidine in Helicobacter pylori-negative subjects: effects of    different regimens. J Gastroenterol 2003; 38:830-835.-   21. Kleinman L, McIntosh E, Ryan M, Schmier J, Crawley J, Locke G R,    III, De L G. Willingness to pay for complete symptom relief of    gastroesophageal reflux disease. Arch Intern Med 2002;    162:1361-1366.-   22. Carlsson R, Galmiche J P, Dent J, Lundell L, Frison L.    Prognostic factors influencing relapse of oesophagitis during    maintenance therapy with antisecretory drugs: a meta-analysis of    long-term omeprazole trials. Aliment Pharmacol Ther 1997;    11:473-482.-   23. Katz P O, Hatlebakk J G, Castell D O. Gastric acidity and acid    breakthrough with twice-daily omeprazole or lansoprazole. Aliment    Pharmacol Ther 2000; 14:709-714.-   24. Tytgat G N. Shortcomings of the first-generation proton pump    inhibitors. Eur J Gastroenterol Hepatol 2001; 13 Suppl 1: S29-S33.-   25. Gedda K, Scott D, Besancon M, Lorentzon P, Sachs G. Turnover of    the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its    effect on inhibition of rat gastric acid secretion. Gastroenterology    1995; 109:1134-1141.-   26. Diamond I, Hurley L S. Histopathology of zinc-deficient fetal    rats. J Nutr 1970; 100:325-329.-   27. Elmes M E, Jones J G. Ultrastructural studies on Paneth cell    apoptosis in zinc deficient rats. Cell Tissue Res 1980; 208:57-63.-   28. Fong L Y, Lee J S, Chan W C, Newberne P M. Zinc deficiency and    the development of esophageal and forestomach tumors in    Sprague-Dawley rats fed precursors of N-nitroso-N-benzylmethylamine.    J Natl Cancer Inst 1984; 72:419-425.-   29. Ng W L, Fong L Y, Ma L, Newberne P M. Dietary zinc deficiency    and tumorigenesis: a scanning electron microscope study. J Electron    Microsc (Tokyo) 1984; 33:344-348.-   30. Sunderman F W, Jr. The influence of zinc on apoptosis. Ann Clin    Lab Sci 1995; 25:134-142.-   31. Cho C H, Fong L Y, Ma P C, Ogle C W. Zinc deficiency: its role    in gastric secretion and stress-induced gastric ulceration in rats.    Pharmacol Biochem Behav 1987; 26:293-297.-   32. Cho C H, Fong L Y, Wong S H, Ogle C W. Zinc deficiency worsens    ethanol-induced gastric ulcers in rats. Drug Nutr Interact 1988;    5:289-295.-   33. Frommer D J. The healing of gastric ulcers by zinc sulphate. Med    J Aust 1975; 2:793-796.-   34. Watanabe T, Arakawa T, Fukuda T, Higuchi K, Kobayashi K. Zinc    deficiency delays gastric ulcer healing in rats. Dig Dis Sci 1995;    40:1340-1344.-   35. Naess K. [Zinc in the treatment of stomach ulcer]. Tidsskr Nor    Laegeforen 1976; 96:1334.-   36. Kirchhoff P, Wagner C A, Gaetzschmann F, Radebold K, Geibel J P.    Demonstration of a functional apical sodium hydrogen exchanger in    isolated rat gastric glands. Am J Physiol Gastrointest Liver Physiol    2003; 285:G1242-G1248.-   37. McDaniel N, Lytle C. Parietal cells express high levels of    Na—K-2Cl cotransporter on migrating into the gastric gland neck. Am    J Physiol 1999; 276:G1273-G1278.-   38. Geibel J P, Wagner C A, Caroppo R, Qureshi I, Gloeckner J,    Manuelidis L, Kirchhoff P, Radebold K. The stomach divalent    ion-sensing receptor scar is a modulator of gastric acid secretion.    J Biol Chem 2001; 276:39549-39552.-   39. Dufner M M, Kirchhoff P, Remy C, Hafner P, Muller M K, Cheng S    X, Tang L Q, Hebert S C, Geibel J P, Wagner C A. The Calcium-Sensing    Receptor (CaSR) acts as a modulator of gastric acid secretion in    freshly isolated human gastric glands. Am J Physiol Gastrointest    Liver Physiol 2005.-   40. Schultheis P J, Clarke L L, Meneton P, Harline M, Boivin G P,    Stemmermann G, Duffy J J, Doetschman T, Miller M L, Shull G E.    Targeted disruption of the murine Na+/H+ exchanger isoform 2 gene    causes reduced viability of gastric parietal cells and loss of net    acid secretion. J Clin Invest 1998; 101:1243-1253.-   41. Kirchhoff P, Andersson K, Socrates T, Sidani S M, Kosiek O,    Geibel J P. Characteristics of the K+-competitive H+,K+-ATPase    Inhibitor AZD0865 in isolated rat gastric glands. Am J Physiol    Gastrointest Liver Physiol 2006.-   42. Andersson K, Carlsson E. Potassium-competitive acid blockade: a    new therapeutic strategy in acid-related diseases. Pharmacol Ther    2005; 108:294-307.-   43. Dammann H G, Burkhardt F. Pantoprazole versus omeprazole:    influence on meal-stimulated gastric acid secretion. Eur J    Gastroenterol Hepatol 1999; 11:1277-1282.

Second Set References

-   1a. Sachs G. The parietal cell as a therapeutic target. Scand J    Gastroenterol Suppl 1986; 118:1-10.-   2a. Lorentzon P, Scott D, Hersey S, Wallmark B, Rabon E, Sachs G.    The gastric H+,K+-ATPase. Prog Clin Biol Res 1988; 273:247-254.-   3a. Wallmark B, Lorentzon P, Sachs G. The gastric H+,K(+)-ATPase. J    Intern Med Suppl 1990; 732:3-8.-   4a. Prinz C, Kajimura M, Scott D, Helander H, Shin J, Besancon M,    Bamberg K, Hersey S, Sachs G. Acid secretion and the H,K ATPase of    stomach. Yale J Biol Med 1992; 65:577-596.-   5a. Scott D R, Helander H F, Hersey S J, Sachs G. The site of acid    secretion in the mammalian parietal cell. Biochim Biophys Acta 1993;    1146:73-80.-   6a. Sachs G, Prinz C, Loo D, Bamberg K, Besancon M, Shin J M.    Gastric acid secretion: activation and inhibition. Yale J Biol Med    1994; 67:81-95.-   7a. Hersey S J, Sachs G. Gastric-Acid Secretion. Physiological    Reviews 1995; 75:155-189.-   8a. Hirschowitz B I, Keeling D, Lewin M, Okabe S, Parsons M, Sewing    K, Wallmark B, Sachs G. Pharmacological Aspects of Acid-Secretion.    Digestive Diseases and Sciences 1995; 40:S3-S23.-   9a. Wolfe M M, Welage L S, Sachs G. Proton pump inhibitors and    gastric acid secretion. Am J Gastroenterol 2001; 96:3467-3468.-   10a. Hersey S J, Sachs G. Gastric-Acid Secretion. Physiological    Reviews 1995; 75:155-189.-   11a. Hersey S J, Sachs G. Gastric-Acid Secretion. Physiological    Reviews 1995; 75:155-189.-   12a. Forte J G, Ly B, Rong Q, Ogihara S, Ramilo M, Agnew B, Yao X.    State of actin in gastric parietal cells. Am J Physiol 1998;    274:C97-104.-   13a. Urushidani T, Forte J G. Signal transduction and activation of    acid secretion in the parietal cell. J Membr Biol 1997; 159:99-111.-   14a. Geibel J P. Role of potassium in acid secretion. World J    Gastroenterol 2005; 11:5259-5265.-   15a. Blachar A, Federle M P. Gastrointestinal complications of    laparoscopic roux-en-Y gastric bypass surgery in patients who are    morbidly obese: findings on radiography and CT. AJR Am J Roentgenol    2002; 179:1437-1442.-   16a. Peghini P L, Katz P O, Castell D O. Ranitidine controls    nocturnal gastric acid breakthrough on omeprazole: a controlled    study in normal subjects. Gastroenterology 1998; 115:1335-1339.-   17a. Peghini P L, Katz P O, Bracy N A, Castell D O. Nocturnal    recovery of gastric acid secretion with twice-daily dosing of proton    pump inhibitors. Am J Gastroenterol 1998; 93:763-767.-   18a. Sanders S W, Moore J G, Day G M, Tolman K G. Circadian    differences in pharmacological blockade of meal-stimulated gastric    acid secretion. Aliment Pharmacol Ther 1992; 6:187-193.-   19a. Knauf F, Yang C L, Thomson R B, Mentone S A, Giebisch G,    Aronson P S. Identification of a chloride-formate exchanger    expressed on the brush border membrane of renal proximal tubule    cells. Proc Natl Acad Sci USA 2001; 98:9425-9430.-   20a. Dufner M M, Kirchhoff P, Remy C, Hafner P, Muller M K, Cheng S    X, Tang L Q, Hebert S C, Geibel J P, Wagner C A. The calcium-sensing    receptor acts as a modulator of gastric acid secretion in freshly    isolated human gastric glands. Am J Physiol Gastrointest Liver    Physiol 2005; 289:G1084-G1090.-   21a. Kirchhoff P, Dave M H, Remy C, Kosiek O, Busque S M, Dufner M,    Geibel J P, Verrey F, Wagner C A. An amino acid transporter involved    in gastric acid secretion. Pflugers Arch 2006; 451:738-748.-   22a. Waisbren S J, Geibel J, Boron W F, Modlin I M. Luminal    perfusion of isolated gastric glands. Am J Physiol 1994;    266:C1013-C1027.-   23a. Waisbren S J, Geibel J P, Modlin I M, Boron W F. Unusual    permeability properties of gastric gland cells. Nature 1994;    368:332-335.-   24a. Busque S M, Kerstetter J E, Geibel J P, Insogna K. L-type amino    acids stimulate gastric acid secretion by activation of the    calcium-sensing receptor in parietal cells. Am J Physiol    Gastrointest Liver Physiol 2005; 289:G664-G669.-   25a. Geibel J P, Wagner C A, Caroppo R, Qureshi I, Gloeckner J,    Manuelidis L, Kirchhoff P, Radebold K. The stomach divalent    ion-sensing receptor scar is a modulator of gastric acid secretion.    J Biol Chem 2001; 276:39549-39552.-   26a. Sachs G, Scott D, Reuben M. Omeprazole and the gastric mucosa.    Digestion 1990; 47 Suppl 1:35-38.-   27a. Sachs G, Wallmark B. The gastric H+,K+-ATPase: the site of    action of omeprazole. Scand J Gastroenterol Suppl 1989; 166:3-11.-   28a. Alino S F, Garcia D, Uvnas-Moberg K. On the interaction between    intragastric pH and electrical vagal stimulation in causing gastric    acid secretion and intraluminal release of gastrin and somatostatin    in anesthetized rats. Acta Physiol Scand 1983; 117:491-495.-   29a. Meulemans A L, Eelen J G, Schuurkes J A. NO mediates gastric    relaxation after brief vagal stimulation in anesthetized dogs. Am J    Physiol 1995; 269:G255-G261.-   30a. Singh J. Prostaglandin release from rat stomach following vagal    stimulation or administration of acetylcholine. Eur J Pharmacol    1980; 65:39-48.-   31a. Aarimaa M, Soderstrom K O, Kalimo H, Inberg M, Nevalainen T.    Morphology and function of the parietal cells after proximal    selective vagotomy in duodenal ulcer patients. Scand J Gastroenterol    1984; 19:787-797.-   32a. Amdrup E. The surgical treatment of duodenal ulcer. Schweiz Med    Wochenschr 1979; 109:583-585.-   33a. Waisbren S J, Modlin I M. The evolution of therapeutic    vagotomy. Surg Gynecol Obstet 1990; 170:261-272.-   34a. Abelo A, Eriksson U G, Karlsson M O, Larsson H, Gabrielsson J.    A turnover model of irreversible inhibition of gastric acid    secretion by omeprazole in the dog. J Pharmacol Exp Ther 2000;    295:662-669.-   35a. Andersen J B, Andrade D V, Wang T. Effects of inhibition    gastric acid secretion on arterial acid-base status during digestion    in the toad Bufo marinus. Comp Biochem Physiol A Mol Integr Physiol    2003; 135:425-433.-   36a. Gedda K, Scott D, Besancon M, Lorentzon P, Sachs G. Turnover of    the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its    effect on inhibition of rat gastric acid secretion. Gastroenterology    1995; 109:1134-1141.-   37a. Sachs G, Shin J M, Pratha V, Hogan D. Synthesis or rupture:    duration of acid inhibition by proton pump inhibitors. Drugs Today    (Barc) 2003; 39 Suppl A:11-14.-   38a. Shamburek R D, Schubert M L. Pharmacology of gastric acid    inhibition. Baillieres Clin Gastroenterol 1993; 7:23-54.-   39a. Locke G R, III. Current medical management of gastroesophageal    reflux disease. Thorac Surg Clin 2005; 15:369-375.-   40a. Geibel J P. Secretion and absorption by colonic crypts. Annu    Rev Physiol 2005; 67:471-490.

1-91. (canceled)
 92. A pharmaceutical composition comprising effectiveamounts of at least one water soluble zinc salt in combination with atleast one therapeutic agent which is favorably orally administered incombination with said water soluble zinc salt, optionally in combinationwith a pharmaceutically acceptable carrier, additive or excipient. 93.The composition according to claim 92 wherein said water soluble zincsalt is selected from the group consisting of zinc acetate, zincascorbate, zinc benzoate, zinc bromide, zinc butyrate, zinc caprylate,zinc carbonate, zinc carnosine, zinc citrate, zinc chloride, zincfluoride, zinc formate, zinc fumarate, zinc fumaric acid monoethylester, zinc gallate, zinc gluconate, zinc glutarate, zinc glycerate,zinc glycerophosphate, zinc glycolate, zinc hydroxide, zinc iodide, zinciodate, zinc lactate, zinc malate, zinc maleate, zinc myristate, zincnitrate, zinc orotate, zinc oxide, zinc phenol sulfonate, zincphosphate, zinc picolinate, zinc picrate, zinc propionate, zincsalicylate, zinc selenate, zinc stearate, zinc succinate, zinc sulfate,zinc tannate, zinc tartrate, zinc undecylenate, zinc valerate, a zincchelate, and mixtures thereof.
 94. The composition according to claim 92wherein said at least one water soluble zinc salt comprises at least twowater soluble zinc salts.
 95. The composition according to claim 92wherein said zinc salt is selected from the group consisting of zincacetate, zinc ascorbate, zinc butryate, zinc carbonate, zinc citrate,zinc chloride, zinc iodide, zinc sulfate, zinc gluconate, zincglycerate, zinc glycolate, zinc formate, zinc lactate, zinc picolinate,zinc propionate, zinc salicylate, zinc succinate, zinc malate, zincmaleate, zinc tartrate, zinc undecylunate, a zinc amino acid chelate andmixtures thereof.
 96. The composition according to claim 94 wherein saidwater soluble zinc salt is selected from the group consisting of zincacetate, zinc ascorbate, zinc benzoate, zinc bromide, zinc butyrate,zinc caprylate, zinc carbonate, zinc carnosine, zinc citrate, zincchloride, zinc fluoride, zinc formate, zinc fumarate, zinc fumaric acidmonoethyl ester, zinc gallate, zinc gluconate, zinc glutarate, zincglycerate, zinc glycerophosphate, zinc glycolate, zinc hydroxide, zinciodide, zinc iodate, zinc lactate, zinc malate, zinc maleate, zincmyristate, zinc nitrate, zinc orotate, zinc oxide, zinc phenolsulfonate, zinc phosphate, zinc picolinate, zinc picrate, zincpropionate, zinc salicylate, zinc selenate, zinc stearate, zincsuccinate, zinc sulfate, zinc tannate, zinc tartrate, zinc undecylenate,zinc valerate, a zinc chelate, and mixtures thereof.
 97. The compositionaccording to claim 94 wherein said zinc salt is selected from the groupconsisting of zinc acetate, zinc ascorbate, zinc butryate, zinccarbonate, zinc citrate, zinc chloride, zinc iodide, zinc sulfate, zincgluconate, zinc glycerate, zinc glycolate, zinc formate, zinc lactate,zinc picolinate, zinc propionate, zinc salicylate, zinc succinate, zincmalate, zinc maleate, zinc tartrate, zinc undecylunate, a zinc aminoacid chelate and mixtures thereof.
 98. The composition according toclaim 92 wherein said therapeutic agent is selected from the groupconsisting of 13-cis-Retinoic Acid; 2-Chlorodeoxyadenosine;5-Azacitidine; 5-Fluorouracil; 6-Mercaptopurine; 6-Thioguanine;Abraxane; Isotretinoin; Actinomycin-D; Doxorubicin Hydrochloride;Anagrelide; Hydrocortisone; Aldesleukin; Alemtuzumab; Pemetrexed;Alitretinoin; Vinblastine; Melphalan; All-transretinoic Acid;AlphaInterferon; Altretamine; Amethopterin; Amifostine;Aminoglutethimide; Aminoglutethimide; Anagrelide; Asparaginase;Hydrocortone Phosphate; Leurocristine; Lenalidomide; Letrozole;Leucovorin; Leukeran; Sargramostim; Leuprolide; Cladribin; LiposomalAra-C; Deltasone; Lomustine; L-phenylalanine mustard; L-Sarcolysin;Leuprolide Acetate; Procarbazine; Maxidex; Mechlorethamine;Mechlorethamine Hydrochloride; Methylprednisolone; Megestrol Acetate;Melphalan; Mercaptopurine; Mesna; Methotrexate; Nilutamide; Anastrozole;Arabinosylcytosine; Darbepoetin Alpha); Pamidronate; Exemestane);Nelarabine; Arsenic Trioxide; Atragen; Bevacizumab; Azacitidine; BCG(Bacillus Calmette Guerin); BCNU (Carmustine); Bexarotene; Tositumomab;Bicalutamide; Bleomycin; Bortezomib; Busulfan; Eribitux; CalciumLeucovorin; Alemtuzumab; Irinotecan hydrochloride; Camptothecin-11;Capecitabine; Carboplatin; Bicalutamide; CC-5013 (Revlimid); CCNU(lomustine); CDDP (Cisplatin); CeeNU; Daunorubicin; Cetuximab;Chlorambucil; Mitomycin; Mitomycin-C; Mitoxantrone; Mustine; Mitomycin;Hydroxyurea; Gemtuzumab Ozogamicin; Vinorelbine Tartrate; Nelarabine;Cyclophosphamide; Pegfilgrastim; Oprelvekin; Filgrastim; Sorafenib;Nilutamide); Pentostatin; Nitrogen Mustard; Genox; Mitoxantrone;Octreotide; Octreotide acetate; Pegylated asparaginase; VincristineSulfate); Denileukin Diftitox; Paclitaxel; Oprevelkin; PrednisoloneSodium Phosphate; Prednisone; Oxaliplatin; Paclitaxel; PaclitaxelProtein-bound; Pamidronate; Panitumumab; Paraplatin; Dactinomycin;Topotecan; Cyclophosphamide; Aminoglutethimide; Cytarabine; CytarabineLiposomal; Dacarbazine; Dacogen; Dactinomycin; Dasatinib; Daunomycin;Daunorubicin; Daunorubicin Hydrochloride; Daunorubicin Liposomal;Decadron; Decitabine; Prednisolone; Prednisone; Denileukin diftitox;Cytarabine liposome; Dexamethasone; Dexamethasone acetate; DexamethasoneSodium Phosphate; Dexasone; Dexrazoxane; Novantrone; Disseminatedintravascular coagulation; Diodex; Docetaxel; Doxorubicin; Hydroxyurea;Dacarbazine; dacarbazine; PEG Interferon; Pegaspargase; Pegfilgrastim;Peginterferon alfa-2b; PEG-L-asparaginase; PEMETREXED; Pentostatin;Phenylalanine Mustard; Procarbazine; Epoetin Alfa; Aldesleukin;Prolifeprospan 20 with Carmustine; Implant; Mercaptopurine; Raloxifene;Lenalidomide; Trexall; Rituximab; (adriamycin); Rubidomycinhydrochloride; Octreotide Acetate; Sargramostim; Hydrocortisone SodiumSuccinate; Methylprednisolone sodium succinate; Sorafenib; Dasatinib;Gleevec; Streptozocin; SU11248; Sunitinib; Sunitinib Malate; Tamoxifen;Erlotinib; Bexarotene; Paclitaxel; Epirubicin hydrochloride;Oxaliplatin; Estramustine; Epirubicin; Epoetin alfa; Cetuximab;Erlotinib; Erwinia L-asparaginase; Ethyol; Etoposide Phosphate;Etoposide; Flutamide; Raloxifene; Exemestane; Toremifene; Fulvestrant;Letrozole; Filgrastim; Floxuridine; Fludarabine; Fluoxymesterone;Flutamide; Folinic Acid; Floxuridine; Fulvestrant; Neupogen; Gefitinib;Gemcitabine; Gemtuzumab; ozogamicin; Gemcitabine); Carmustine Wafer;Goserelin; Granulocyte Colony Stimulating Factor; Docetaxel;Temozolomide; Teniposide; Thiotepa; Thalidomide; BCG (TheraCys strain);Thioguanine; Thiophosphamide; Thiotepa; Etoposide; Topotecan;Toremifene; Tositumomab; Trastuzumab; Tretinoin; Arsenic; VCR;Panitumumab; Vinblastine Sulfate Bortezomib; Azacitidine; Vinblastine;Vinblastine Sulfate; Vincristine; Vinorelbine; Vinorelbine tartrate;VM-26; Vorinostat; Teniposide; Capecitabine); Streptozocin;Fluoxymesterone; Trastuzumab; Hexadrol; Altretamin; Hexamethylmelamine;Hycamtin; Hydroxyurea; Ibritumomab; Ibritumomab Tiuxetan; Idarubicin;Idarubicin; Ifosfamide; IFN-alpha; IL-11; IL-2; Imatinib mesylate;Imidazole Carboxamide; Interferon alfa; Interferon Alfa-2b (PEGConjugate); Interleukin-2; Interleukin-11; interferon alfa-2b;Getfitinib; Irinotecan; Isotretinoin; Dexrazoxane; Goserelin; Zoledronicacid; Zolinza and mixtures thereof.
 99. The composition according toclaim 92 wherein said therapeutic agent is a chemotherapeutic agent.100. The composition according to claim 92 wherein said therapeuticagent is a non-steroidal antiinflammatory drug (NSAID).
 101. Thecomposition according to claim 92 wherein said therapeutic agent is animmunosuppressive agent.
 102. The composition according to claim 92wherein said therapeutic agent is an anti-asthma agent.
 103. Thecomposition according to claim 92 wherein said therapeutic agent is astatin.
 104. A method of increasing the bioavailability and/or reducingor alleviating the side effects of an orally administered therapeuticcompound comprising coadministering with an effective amount of saidcompound an amount of at least one water soluble zinc salt effective toenhance the bioavailability and/or reduce or alleviate the side effectsof said therapeutic compound.
 105. The method according to claim 104wherein said water soluble zinc salt is selected from the groupconsisting of zinc acetate, zinc ascorbate, zinc benzoate, zinc bromide,zinc butyrate, zinc caprylate, zinc carbonate, zinc carnosine, zinccitrate, zinc chloride, zinc fluoride, zinc formate, zinc fumarate, zincfumaric acid monoethyl ester, zinc gallate, zinc gluconate, zincglutarate, zinc glycerate, zinc glycerophosphate, zinc glycolate, zinchydroxide, zinc iodide, zinc iodate, zinc lactate, zinc malate, zincmaleate, zinc myristate, zinc nitrate, zinc orotate, zinc oxide, zincphenol sulfonate, zinc phosphate, zinc picolinate, zinc picrate, zincpropionate, zinc salicylate, zinc selenate, zinc stearate, zincsuccinate, zinc sulfate, zinc tannate, zinc tartrate, zinc undecylenate,zinc valerate, a zinc chelate, and mixtures thereof.
 106. The methodaccording to claim 104 or 105 wherein said at least one water solublezinc salt comprises at least two water soluble zinc salts.
 107. Themethod according to claim 106 wherein said zinc salts are selected fromthe group consisting of zinc acetate, zinc ascorbate, zinc butryate,zinc carbonate, zinc citrate, zinc chloride, zinc iodide, zinc sulfate,zinc gluconate, zinc glycerate, zinc glycolate, zinc formate, zinclactate, zinc picolinate, zinc propionate, zinc salicylate, zincsuccinate, zinc malate, zinc maleate, zinc tartrate, zinc undecylunate,a zinc amino acid chelate and mixtures thereof.
 108. The methodaccording to claim 106 wherein said water soluble zinc salts areselected from the group consisting of zinc acetate, zinc ascorbate, zincbenzoate, zinc bromide, zinc butyrate, zinc caprylate, zinc carbonate,zinc carnosine, zinc citrate, zinc chloride, zinc fluoride, zincformate, zinc fumarate, zinc fumaric acid monoethyl ester, zinc gallate,zinc gluconate, zinc glutarate, zinc glycerate, zinc glycerophosphate,zinc glycolate, zinc hydroxide, zinc iodide, zinc iodate, zinc lactate,zinc malate, zinc maleate, zinc myristate, zinc nitrate, zinc orotate,zinc oxide, zinc phenol sulfonate, zinc phosphate, zinc picolinate, zincpicrate, zinc propionate, zinc salicylate, zinc selenate, zinc stearate,zinc succinate, zinc sulfate, zinc tannate, zinc tartrate, zincundecylenate, zinc valerate, a zinc chelate, and mixtures thereof. 109.The method according to claim 108 wherein said zinc salts are selectedfrom the group consisting of zinc acetate, zinc ascorbate, zincbutryate, zinc carbonate, zinc citrate, zinc chloride, zinc iodide, zincsulfate, zinc gluconate, zinc glycerate, zinc glycolate, zinc formate,zinc lactate, zinc picolinate, zinc propionate, zinc salicylate, zincsuccinate, zinc malate, zinc maleate, zinc tartrate, zinc undecylunate,a zinc amino acid chelate and mixtures thereof.
 110. The methodaccording to any of claims 104-109 wherein said therapeutic agent isselected from the group consisting of 13-cis-Retinoic Acid;2-Chlorodeoxyadenosine; 5-Azacitidine; 5-Fluorouracil; 6-Mercaptopurine;6-Thioguanine; Abraxane; Isotretinoin; Actinomycin-D; DoxorubicinHydrochloride; Anagrelide; Hydrocortisone; Aldesleukin; Alemtuzumab;Pemetrexed; Alitretinoin; Vinblastine; Melphalan; All-transretinoicAcid; AlphaInterferon; Altretamine; Amethopterin; Amifostine;Aminoglutethimide; Aminoglutethimide; Anagrelide; Asparaginase;Hydrocortone Phosphate; Leurocristine; Lenalidomide; Letrozole;Leucovorin; Leukeran; Sargramostim; Leuprolide; Cladribin; LiposomalAra-C; Deltasone; Lomustine; L-phenylalanine mustard; L-Sarcolysin;Leuprolide Acetate; Procarbazine; Maxidex; Mechlorethamine;Mechlorethamine Hydrochloride; Methylprednisolone; Megestrol Acetate;Melphalan; Mercaptopurine; Mesna; Methotrexate; Nilutamide; Anastrozole;Arabinosylcytosine; Darbepoetin Alpha); Pamidronate; Exemestane);Nelarabine; Arsenic Trioxide; Atragen; Bevacizumab; Azacitidine; BCG(Bacillus Calmette Guerin); BCNU (Carmustine); Bexarotene; Tositumomab;Bicalutamide; Bleomycin; Bortezomib; Busulfan; Eribitux; CalciumLeucovorin; Alemtuzumab; Irinotecan hydrochloride; Camptothecin-11;Capecitabine; Carboplatin; Bicalutamide; CC-5013 (Revlimid); CCNU(lomustine); CDDP (Cisplatin); CeeNU; Daunorubicin; Cetuximab;Chlorambucil; Mitomycin; Mitomycin-C; Mitoxantrone; Mustine; Mitomycin;Hydroxyurea; Gemtuzumab Ozogamicin; Vinorelbine Tartrate; Nelarabine;Cyclophosphamide; Pegfilgrastim; Oprelvekin; Filgrastim; Sorafenib;Nilutamide); Pentostatin; Nitrogen Mustard; Genox; Mitoxantrone;Octreotide; Octreotide acetate; Pegylated asparaginase; VincristineSulfate); Denileukin Diftitox; Paclitaxel; Oprevelkin; PrednisoloneSodium Phosphate; Prednisone; Oxaliplatin; Paclitaxel; PaclitaxelProtein-bound; Pamidronate; Panitumumab; Paraplatin; Dactinomycin;Topotecan; Cyclophosphamide; Aminoglutethimide; Cytarabine; CytarabineLiposomal; Dacarbazine; Dacogen; Dactinomycin; Dasatinib; Daunomycin;Daunorubicin; Daunorubicin Hydrochloride; Daunorubicin Liposomal;Decadron; Decitabine; Prednisolone; Prednisone; Denileukin diftitox;Cytarabine liposome; Dexamethasone; Dexamethasone acetate; DexamethasoneSodium Phosphate; Dexasone; Dexrazoxane; Novantrone; Disseminatedintravascular coagulation; Diodex; Docetaxel; Doxorubicin; Hydroxyurea;Dacarbazine; dacarbazine; PEG Interferon; Pegaspargase; Pegfilgrastim;Peginterferon alfa-2b; PEG-L-asparaginase; PEMETREXED; Pentostatin;Phenylalanine Mustard; Procarbazine; Epoetin Alfa; Aldesleukin;Prolifeprospan 20 with Carmustine; Implant; Mercaptopurine; Raloxifene;Lenalidomide; Trexall; Rituximab; (adriamycin); Rubidomycinhydrochloride; Octreotide Acetate; Sargramostim; Hydrocortisone SodiumSuccinate; Methylprednisolone sodium succinate; Sorafenib; Dasatinib;Gleevec; Streptozocin; SU11248; Sunitinib; Sunitinib Malate; Tamoxifen;Erlotinib; Bexarotene; Paclitaxel; Epirubicin hydrochloride;Oxaliplatin; Estramustine; Epirubicin; Epoetin alfa; Cetuximab;Erlotinib; Erwinia L-asparaginase; Ethyol; Etoposide Phosphate;Etoposide; Flutamide; Raloxifene; Exemestane; Toremifene; Fulvestrant;Letrozole; Filgrastim; Floxuridine; Fludarabine; Fluoxymesterone;Flutamide; Folinic Acid; Floxuridine; Fulvestrant; Neupogen; Gefitinib;Gemcitabine; Gemtuzumab; ozogamicin; Gemcitabine); Carmustine Wafer;Goserelin; Granulocyte Colony Stimulating Factor; Docetaxel;Temozolomide; Teniposide; Thiotepa; Thalidomide; BCG (TheraCys strain);Thioguanine; Thiophosphamide; Thiotepa; Etoposide; Topotecan;Toremifene; Tositumomab; Trastuzumab; Tretinoin; Arsenic; VCR;Panitumumab; Vinblastine Sulfate Bortezomib; Azacitidine; Vinblastine;Vinblastine Sulfate; Vincristine; Vinorelbine; Vinorelbine tartrate;VM-26; Vorinostat; Teniposide; Capecitabine); Streptozocin;Fluoxymesterone; Trastuzumab; Hexadrol; Altretamin; Hexamethylmelamine;Hycamtin; Hydroxyurea; Ibritumomab; Ibritumomab Tiuxetan; Idarubicin;Idarubicin; Ifosfamide; IFN-alpha; IL-11; IL-2; Imatinib mesylate;Imidazole Carboxamide; Interferon alfa; Interferon Alfa-2b (PEGConjugate); Interleukin-2; Interleukin-11; interferon alfa-2b;Getfitinib; Irinotecan; Isotretinoin; Dexrazoxane; Goserelin; Zoledronicacid; Zolinza and mixtures thereof.
 110. The method according to claim104 wherein said therapeutic agent is a chemotherapeutic agent.
 111. Themethod according to claim 104 wherein said therapeutic agent is anon-steroidal antiinflammatory drug (NSAID).
 112. The method accordingto claim 104 wherein said therapeutic agent is an immunosuppressiveagent.
 113. The method according to claim 104 wherein said therapeuticagent is an anti-asthma agent.
 114. The method according to claim 104wherein said therapeutic agent is a statin.